Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Neuromyelitis Optica. Core disease mechanisms, molecular and cellular path...

This report is retrieval-only and is generated directly from Asta results.

• Papers retrieved: 20
• Snippets retrieved: 20

Relevant Papers

[1] Unraveling the Immunopathogenesis of Multiple Sclerosis: The Dynamic Dance of Plasmablasts and Pathogenic T Cells

• Authors: Y. Matsuzaka, R. Yashiro
• Year: 2023
• Venue: Biologics
• URL: https://www.semanticscholar.org/paper/a560fba99a3b87c378dd7e6027dda1a80de312d6
• DOI: 10.3390/biologics3030013
• Citations: 1
• Influential citations: 1
• Summary: From this understanding of the immune regulation of MS, the development of therapeutic strategies that target only pathogenic immune cells can be expected and the restoration of weakened immune regulatory functions may be a true disease-modifying treatment.
• Evidence snippets:
• Snippet 1 (score: 0.524) > Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system, characterized by multiple lesions occurring temporally and spatially [1]. However, the details of the mechanism of onset have not been clarified. The diagnosis is usually confirmed by demonstrating temporal and spatial multifocal lesions through detailed medical history and neurological examination over time and ruling out other diseases [2]. On the other hand, patients presenting with symptoms primarily of optic nerve and spinal cord origin include those with neuromyelitis optica spectrum disorders (NMOSD), originally known as a non-recurring disease with an inflammatory background that severely damages the optic nerve and spinal cord in a relatively short period of time [3]. However, in recent years, it has become clear that recurrent pathology is common, and the involvement of serum anti-aquaporin 4 (AQP4) antibodies in pathogenesis is being elucidated [4]. Furthermore, among AQP4 antibody-positive patients, there are various patterns of NMOSD, such as those with lesions not only in the optic nerve and spinal cord but also in the brain; those with lesions only in the spinal cord or optic nerve; and those who are negative for AQP4 antibodies but have symptoms characteristic of NMOSD. > The currently used disease-modifying drugs can effectively reduce relapses but are not effective in primary progressive disease. Furthermore, it is impossible to halt the progression of the disorder once it enters the secondary progressive stage, even in the relapsing tolerant type. Therefore, it is considered important to diagnose and start treatment as early as possible. In this review, we summarize the genetic and environmental factors, pathological animal models, cellular and molecular mechanisms, and clinical treatment strategies of MS with our current understanding of the novel molecular mechanisms of pathogenesis (Table 1). The basic pathology of MS is "inflammatory demyelination" and many attempts have been made to find the cause of this inflammation [1,2].

[2] Optical Coherence Tomography and Magnetic Resonance Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder

• Authors: Praveena Manogaran, J. Hanson, Elisabeth D. Olbert, Christine Egger, C. Wicki et al.
• Year: 2016
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/fa650dacd817d9a5f996bf7de0b40dc6afd0fcb8
• DOI: 10.3390/ijms17111894
• PMID: 27854301
• PMCID: 5133893
• Citations: 35
• Influential citations: 1
• Summary: This review focuses on the current knowledge of the role of the visual pathway using OCT and MRI in patients with MS and NMOSD, and emphasis is placed on studies that employ both MRI and OCT to investigate damage to the visual system in these diseases.
• Evidence snippets:
• Snippet 1 (score: 0.500) > Multiple sclerosis (MS) is a chronic autoimmune inflammatory disorder of the central nervous system (CNS) in which different environmental factors act on the basis of a multi-genetic trait [1,2]. It is characterized by focal demyelinating plaques and diffuse neurodegeneration throughout the white and gray matter [3,4]. Approximately two million people worldwide are affected by this disorder, and it is the most common non-traumatic neurological disability affecting young adults [5]. Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune astrocytopathic disease of the CNS that preferentially involves the optic nerve and spinal cord [6,7]. The identification of the disease-specific NMO-immunoglobulin G (NMO-IgG) and its effects on astrocytic aquaporin-4 (AQP4) water channels has helped to facilitate differentiation of NMOSD from MS [8]. Nevertheless, imaging and clinical manifestations frequently overlap, particularly in the early stages of the diseases and in NMOSD patients testing negative for AQP4-IgG antibodies [7]. The exact pathophysiological mechanisms behind MS and NMOSD have still not been fully elucidated; however, there is evidence that tissue injury and demyelination in MS is mediated by T-cell activity [9]. Axonal and neuronal atrophy is likely a secondary effect of inflammatory demyelination but can also occur as a result of independent subclinical disease activity [9]. Neuro-axonal degeneration (in addition to demyelination) has recently been considered more relevant in MS pathophysiology; it has been documented in both active and inactive lesions, distal to the areas affected by autoimmune inflammation, and early in the disease course [10]. Conversely, the pathophysiology in NMOSD predominantly involves the deposition of IgG and complement, resulting in a loss of AQP4 proteins on astrocytes and severe neuronal and axonal loss [6]. > Both diseases present with significant clinical and pathological heterogeneity between individuals.

[3] Research hotspots and emerging topics in neuromyelitis optica spectrum disorder treatment: Insights from a bibliometric analysis

• Authors: Juan Wang, Guangbiao Cai, Shuang Xia, J. Qin, Ben Liu
• Year: 2025
• Venue: Medicine
• URL: https://www.semanticscholar.org/paper/e16edbb1e19a145ebe90cb544ac347c2df815c38
• DOI: 10.1097/MD.0000000000042850
• PMID: 40489809
• PMCID: 12150997
• Summary: This bibliometric analysis provides for the first time a comprehensive framework and frontier hot spot analysis in the field of NMOSD treatment, offering references for researchers in the field and contributing to the further development of the field.
• Evidence snippets:
• Snippet 1 (score: 0.478) > Neuromyelitis optica spectrum disorder (NMOSD) encompasses a range of inflammatory conditions that are characterized by recurrent episodes, with the optic nerves and spinal cord being the main sites of involvement. From a microscopic perspective, patients produce a specific autoantibody known as aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). This antibody binds to AQP4 on the astrocytic foot processes at the surface of microvessels, the spinal cord gray matter, the ocular globe, the subarachnoid space of the optic nerve, around the mesencephalic aqueduct, and the periventricular regions, forming immune complexes. This, in turn, activates the complement immune system to produce an immune response, leading to demyelination, neuronal damage, and necrosis. [1,2] Approximately 70% to 80% of individuals with NMOSD exhibit positive results for AQP4-IgG antibody testing. The antibody triggers the disease through various mechanisms, including inflammatory responses, amplification of immune responses, antibody-dependent cellular cytotoxicity, disruption of aquaporin function, early granulocyte recruitment, and complement-dependent cytotoxicity. Studies have shown that undiagnosed and untreated NMOSD patients are associated with disability and poor prognosis, and the degree of disability accumulates with each relapse. Therefore, preventing relapses is crucial in the disease management of NMOSD. [3] ith a deeper understanding of its pathological mechanisms, the therapy for NMOSD is rapidly evolving and gradually becoming a research focus. These treatment strategies aim to control the disease, reduce relapse rates, alleviate the progression of disability, and elevate the living standards of patients by precisely regulating the relevant molecular and cellular pathways. > Bibliometrics, functioning as a thorough and unbiased approach to scientific data analysis, offers an advantageous way to delve into the knowledge architecture, developmental trajectories, hotspots, trends, and the contributions of various researchers, institutions, and countries. [4]

[4] The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review

• Authors: Alessander Leyendecker Jr., C. Pinheiro, M. Amano, D. Bueno
• Year: 2018
• Venue: Frontiers in Immunology
• URL: https://www.semanticscholar.org/paper/c68257f1169b10b00ea537555272b2ce76c263aa
• DOI: 10.3389/fimmu.2018.02056
• PMID: 30254638
• PMCID: 6141714
• Citations: 82
• Influential citations: 2
• Summary: The results obtained in this study open new avenues for the treatment of immune-related diseases through the administration of hMSCs and emphasize the importance of the conduction of further studies in this area.
• Evidence snippets:
• Snippet 1 (score: 0.477) > Finally, a study conducted by Ulusoy et al. (147) reported a decrease in the serum levels of anti-muscle-specific tyrosine kinase antibodies after the treatment with hMSCs. Likewise, this study described a reduction in the percentages of neuromuscular junction IgG in the serum and complement component three deposits in the muscles of mice treated with hMSCs. It can be, therefore, speculated that the reduction in the severity and clinical manifestations of the disease observed after hMSCs administration is a direct result of the inhibitory effect of these stem cells in activation and proliferation of B cells. As a consequence, the secretion of IgG autoantibodies such as the anti-acetylcholine receptor antibody and the anti-musclespecific tyrosine kinase antibody by hyperstimulated B-cells also decreases, culminating in the inhibition in the progression of the disease. > Neuromyelitis optica is an inflammatory, demyelinating, and autoimmune disease of the central nervous system, which selectively affects the spinal cord and optic nerves, simultaneously or sequentially. Symptoms of neuromyelitis optica include loss of vision, sensitivity changes, muscle weakness, spasticity, incoordination, ataxia, urinary and fecal incontinence, and autonomic dysfunctions in parts of the trunk and limbs supplied by nerves coming out of the spine below the spinal lesion (215). Clinical and serological evidence of autoimmunity associated with B cells has been observed in patients with neuromyelitis optica, in whom demyelinating lesions exhibit perivascular immunoglobulin deposition, local activation of the complement cascade and eosinophilic infiltration (216). Other mechanisms involved in this humoral response are the secretion of IL-2, anti-myelin autoantibodies, oligodendrocyte-associated anti-glycoprotein autoantibodies, and IgG autoantibodies against the astroglial water channel aquaporin-4 (217). In general, neuromyelitis optica attacks are more severe than those of multiple sclerosis and are commonly fatal (215).

[5] Neuromyelitis optica (NMO)‐IgG‐driven organelle reorganization in human iPSC‐derived astrocytes

• Authors: Sukhee Cho, Hyein Lee, Minkyo Jung, Kirim Hong, Seung-Hwa Woo et al.
• Year: 2021
• Venue: The FASEB Journal
• URL: https://www.semanticscholar.org/paper/d9653662b93a3c95c53f2aaee0b3dc5ef97ee834
• DOI: 10.1096/fj.202100637R
• PMID: 34460995
• PMCID: 12316078
• Citations: 6
• Summary: It is observed that NMO‐IgG induces structural alterations in mitochondria and their association with the endoplasmic reticulum (ER) and lysosomes at the ultrastructural level, which potentially leads to impaired mitochondrial functions and dynamics, and human astrocytes display impaired mitochondrial bioenergetics and autophagy activity.
• Evidence snippets:
• Snippet 1 (score: 0.457) > Neuromyelitis optica (NMO) is a primary astrocytic disease associated with inflammation and secondary myelin loss in the central nervous system (CNS). 1 The presence of autoantibodies (NMO-IgG) in patient sera targeting aquaporin 4 (AQP4), a water channel, is an important clinical biomarker that plays a central role in disease pathogenesis. 2,3 In the CNS, AQP4 is predominantly expressed in astrocytes, especially on their end-foot processes. 4 Upon NMO-IgG binding to AQP4, endocytosis is initiated, which consequently reduces AQP4 membrane levels. 5,6 The interaction between NMO-IgG and astrocytic AQP4 leads to the synthesis of components of the complement system and cytokines, which contribute to pathogenesis in other cell types such as microglia. 7,8 While NMO-IgG plays a central role in disease pathogenesis, the cellular changes driven by NMO-IgG in astrocytes and their associated molecular mechanisms are largely unknown. > Astrocytes are key components of the CNS. They provide trophic support for synaptogenesis, maintain a homeostatic environment, regulate synaptic activity, and sustain the metabolic needs of neurons. [9][10][11] Dysfunctional astrocytes are associated with multiple CNS disorders, including epilepsy, inflammatory demyelinating diseases, metabolic disorders, and neurodegenerative disorders. 12 Changes in astrocyte morphology, gene expression, and intracellular organelle networks are largely linked to their functions. [13][14][15][16] Recent studies have suggested the importance of understanding the mechanisms of organelle remodeling and subsequent functional alterations in astrocytes under pathological conditions, such as neuroinflammation and neurodegeneration. [16][17][18][19] Fundamental biology of astrocytes and pathogenic changes in NMO has been uncovered by rodent systems, which provide the groundwork for human studies. [5][6][7][8][20][21][22][23] To complement animal models and further our understanding of pathogenic mechanisms in

[6] Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies

• Authors: Edgar Carnero Contentti, J. Correale
• Year: 2021
• Venue: Journal of Neuroinflammation
• URL: https://www.semanticscholar.org/paper/24d72ed7ca0debc3bd49c5d9a142536567cbf6d3
• DOI: 10.1186/s12974-021-02249-1
• PMID: 34530847
• PMCID: 8444436
• Citations: 259
• Influential citations: 6
• Summary: A descriptive review of the new evidence on NMOSD pathophysiology and of preliminary results from ongoing trials with new drugs is presented, highlighting promising treatment modalities as well as auspicious preclinical and clinical studies.
• Evidence snippets:
• Snippet 1 (score: 0.456) > During the last two decades, significant advances have been made in NMOSD, including: introduction of new diagnostic criteria (gray arrows), identification of biomarkers, better characterization of clinical phenotypes, improved prognosis and new therapeutic approaches (black arrows). AQP4 aquaporin-4, AQP4-ab aquaporin-4-antibodies, IgG immunoglobulin G, IPND International Panel for NMO Diagnosis, MOG myelin-oligodendrocyte glycoprotein, NMO neuromyelitis optica, NMOSD neuromyelitis optica spectrum disorder, TM transverse myelitis treatment of acute episodes, individual symptom management, and long-term relapse prevention. > Long-term relapse prevention includes treatments based on data from retrospective observations, and prospective observational studies without control groups. The most commonly used treatments include azathioprine (AZA), mycophenolate (MMF), and rituximab [18]. In the last 2 years however, four pivotal randomized clinical trials (RCT) have expanded the spectrum of drugs available for NMOSD patients. Phase 3 studies have shown significant relapse reduction compared to placebo, in patients treated with monoclonal antibodies against the interleukin-6 receptor ([IL-6R]; satralizumab) [19,20], against CD 19 present on CD19-expressing B cells (inebilizumab) [21], and against the C5 fraction of complement (eculizumab) [13]. This effect was particularly found in AQP4-ab-positive NMOSD patients in all three trials [13,19,20]. > We therefore present a review on the most relevant findings as well as the auspicious preclinical and clinical study results, in light of additional evidence on molecular mechanisms underlying NMOSD, and ongoing trials of new drugs for treating this condition.

[7] Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies

• Authors: Edgar Carnero Contentti, J. Correale
• Year: 2021
• Venue: Journal of Neuroinflammation
• URL: https://www.semanticscholar.org/paper/c0667cc145e48c228cbffee6237be11a3785ab20
• DOI: 10.1186/s12974-021-02249-1
• Summary: A descriptive review of the new evidence on NMOSD pathophysiology and of preliminary results from ongoing trials with new drugs is presented, highlighting promising treatment modalities as well as auspicious preclinical and clinical studies.
• Evidence snippets:
• Snippet 1 (score: 0.456) > During the last two decades, significant advances have been made in NMOSD, including: introduction of new diagnostic criteria (gray arrows), identification of biomarkers, better characterization of clinical phenotypes, improved prognosis and new therapeutic approaches (black arrows). AQP4 aquaporin-4, AQP4-ab aquaporin-4-antibodies, IgG immunoglobulin G, IPND International Panel for NMO Diagnosis, MOG myelin-oligodendrocyte glycoprotein, NMO neuromyelitis optica, NMOSD neuromyelitis optica spectrum disorder, TM transverse myelitis treatment of acute episodes, individual symptom management, and long-term relapse prevention. > Long-term relapse prevention includes treatments based on data from retrospective observations, and prospective observational studies without control groups. The most commonly used treatments include azathioprine (AZA), mycophenolate (MMF), and rituximab [18]. In the last 2 years however, four pivotal randomized clinical trials (RCT) have expanded the spectrum of drugs available for NMOSD patients. Phase 3 studies have shown significant relapse reduction compared to placebo, in patients treated with monoclonal antibodies against the interleukin-6 receptor ([IL-6R]; satralizumab) [19,20], against CD 19 present on CD19-expressing B cells (inebilizumab) [21], and against the C5 fraction of complement (eculizumab) [13]. This effect was particularly found in AQP4-ab-positive NMOSD patients in all three trials [13,19,20]. > We therefore present a review on the most relevant findings as well as the auspicious preclinical and clinical study results, in light of additional evidence on molecular mechanisms underlying NMOSD, and ongoing trials of new drugs for treating this condition.

[8] Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G

• Authors: Nithi Asavapanumas, J. Ratelade, M. Papadopoulos, J. Bennett, M. Levin et al.
• Year: 2014
• Venue: Journal of Neuroinflammation
• URL: https://www.semanticscholar.org/paper/199771378a4db5fed5222917704fba5ee63d7729
• DOI: 10.1186/1742-2094-11-16
• PMID: 24468108
• PMCID: 3909205
• Citations: 61
• Influential citations: 5
• Summary: Passive transfer of NMO-IgG and complement by continuous infusion near the optic chiasm in mice is sufficient to produce ON with characteristic NMO pathology, and should be useful in further studies of N MO pathogenesis mechanisms and therapeutics.
• Evidence snippets:
• Snippet 1 (score: 0.451) > Neuromyelitis optica (NMO) is an autoimmune inflammatory disease of the central nervous system that causes demyelinating lesions in optic nerve and spinal cord, leading to loss of visual and motor function [1][2][3]. A specific feature of NMO is the presence of serum immunoglobulin G (IgG) autoantibodies (NMO-IgG) against astrocyte water channel aquaporin-4 (AQP4) [4,5]. NMO pathogenesis is thought to involve NMO-IgG binding to AQP4 on astrocytes, which causes complement-and cell-mediated astrocyte cytotoxicity, inflammation, and blood-brain barrier (BBB) disruption, with secondary oligodendrocyte and neuron damage [6][7][8]. Current therapies of NMO include general immunosuppression, B-cell depletion and plasma exchange [9,10]. > Although optic neuritis (ON) with permanent loss of vision is a major clinical feature of NMO [11][12][13], adequate models of NMO ON are lacking. The particular sensitivity of the optic nerve in NMO suggests the need to study disease mechanisms and treatment responses in optic nerve-specific NMO models. Disease-relevant animal models of NMO are important for investigating pathogenesis mechanisms, such as the role of inflammatory effector cells [14][15][16] and for testing of potential therapeutics such as antibodies targeting AQP4 [17] or complement [18,19]. The original models of NMO involved administration of NMO-IgG to rats with pre-existing neuroinflammation produced by experimental autoimmune encephalomyelitis, in which immunization with a myelin oligopeptide produces an anti-myelin T-cell response [20][21][22]. Subsequently, a passive-transfer mouse model of NMO involving intracranial injection of NMO-IgG and human complement recapitulated key pathological findings in NMO, including loss of AQP4 and glial fibrillary acidic protein (GFA

[9] Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders

• Authors: T. Akaishi, Toshiyuki Takahashi, T. Misu, Michiaki Abe, T. Ishii et al.
• Year: 2020
• Venue: Scientific Reports
• URL: https://www.semanticscholar.org/paper/a5e9449cd7d204533f5484f7c4f77b96fef78acb
• DOI: 10.1038/s41598-020-70919-w
• PMID: 32807848
• PMCID: 7431838
• Citations: 65
• Influential citations: 1
• Summary: Clinical deterioration in NMOSD patients is irreversible and almost exclusively takes place at the timing of clinical attacks with stepwise accumulation of neurological disability, while changes in EDSS score can be seen apart from relapses in MS patients.
• Evidence snippets:
• Snippet 1 (score: 0.451) > The progressive patterns of neurological disability in multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) and the significance of clinical relapses to the progressions of neurological disability in these diseases have not been fully elucidated. In this study, to elucidate the impact of relapses to the progression of accumulated neurological disability and to identify the factors to affect the progression of neurological disability in MS and NMOSD, we followed 62 consecutive MS patients and 33 consecutive NMOSD patients for more than 5 years with the clinical symptoms, relapse occurrence, and Expanded Disability Status Scale (EDSS) in the chronic phase. All enrolled MS patients were confirmed to be negative for serum anti-myelin oligodendrocyte glycoprotein antibody. As a result, patients with NMOSD showed significantly severer neurological disability at 5 years from onset than MS patients. Progression in EDSS score was almost exclusively seen after clinical attacks in NMOSD, whereas progression could be observed apart from relapses in MS. Neurological disability did not change without attacks in NMOSD, whereas it sometimes spontaneously improved or deteriorated apart from relapses in MS (p < 0.001). In patients with MS, those with responsible lesions primarily in spinal cord were more likely to show such spontaneous improvement. In conclusion, clinical deterioration in NMOSD patients is irreversible and almost exclusively takes place at the timing of clinical attacks with stepwise accumulation of neurological disability. Meanwhile, changes in EDSS score can be seen apart from relapses in MS patients. Neurological disability in MS patients is partly reversible, and the patients with disease modifying drugs sometimes present spontaneous improvement of the neurological disability. > Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are major autoimmune-related neurological diseases that predominantly impairs the central nervous system (CNS) but have distinct pathophysiological mechanisms 1,2 . Both diseases typically present recurrent clinical attacks with lesions in cerebrum, optic nerves, brainstem, and spinal cord 1,3 .

[10] Bioenergetic Failure in Rat Oligodendrocyte Progenitor Cells Treated with Cerebrospinal Fluid Derived from Multiple Sclerosis Patients

• Authors: Deepali Mathur, A. Riffo-Campos, J. Castillo, J. Haines, Ó. G. Vidaurre et al.
• Year: 2017
• Venue: Frontiers in Cellular Neuroscience
• URL: https://www.semanticscholar.org/paper/0c10bb85a037674a2360de1661c9858850536a46
• DOI: 10.3389/fncel.2017.00209
• PMID: 28775680
• PMCID: 5517784
• Citations: 11
• Summary: The findings revealed downregulated expression of genes involved in carbohydrate metabolism, and that glucose metabolism impairment and reduced ATP availability for cellular damage repair clearly differentiate more benign forms from the most aggressive forms and worst prognosis in MS patients.
• Evidence snippets:
• Snippet 1 (score: 0.448) > In relapsing-remitting multiple sclerosis (RRMS) subtype, the patient's brain itself is capable of repairing the damage, remyelinating the axon and recovering the neurological function. Cerebrospinal fluid (CSF) is in close proximity with brain parenchyma and contains a host of proteins and other molecules, which influence the cellular physiology, that may balance damage and repair of neurons and glial cells. The purpose of this study was to determine the pathophysiological mechanisms underpinning myelin repair in distinct clinical forms of MS and neuromyelitis optica (NMO) patients by studying the effect of diseased CSF on glucose metabolism and ATP synthesis. A cellular model with primary cultures of oligodendrocyte progenitor cells (OPCs) from rat cerebrum was employed, and cells were treated with CSF from distinct clinical forms of MS, NMO patients and neurological controls. Prior to comprehending mechanisms underlying myelin repair, we determine the best stably expressed reference genes in our experimental condition to accurately normalize our target mRNA transcripts. The GeNorm and NormFinder algorithms showed that mitochondrial ribosomal protein (Mrpl19), hypoxanthine guanine phosphoribosyl transferase (Hprt), microglobulin β2 (B2m), and transferrin receptor (Tfrc) were identified as the best reference genes in OPCs treated with MS subjects and were used for normalizing gene transcripts. The main findings on microarray gene expression profiling analysis on CSF treated OPCs cells revealed a disturbed carbohydrate metabolism and ATP synthesis in MS and NMO derived CSF treated OPCs. In addition, using STRING program, we investigate whether gene-gene interaction affected the whole network in our experimental conditions.

[11] Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder

• Authors: Eun Bin Cho, Ju-Hong Min, Patrick Waters, Miyoung Jeon, Eun-Seon Ju et al.
• Year: 2024
• Venue: Frontiers in Immunology
• URL: https://www.semanticscholar.org/paper/5f3f33c0449de66063a546e4c16de7a5dac452e9
• DOI: 10.3389/fimmu.2024.1320094
• PMID: 38576611
• PMCID: 10991751
• Citations: 8
• Summary: A higher prominence of complement pathway activation and subsequent C3 degradation in MOGAD compared to AQP4-NMOSD is indicated, implying a strong regulation of the complement system, implying its potential involvement in the pathogenesis of MOGAD through mechanisms that extend beyond TCC formation.
• Evidence snippets:
• Snippet 1 (score: 0.442) > Neuromyelitis optica spectrum disorders (NMOSD) are chronic inflammatory diseases of the central nervous system (CNS) that preferentially affects the optic nerve, spinal cord, and certain brain regions. The discovery of pathogenic antibodies that target aquaporin-4 (AQP4-immunoglobulin G [IgG]) facilitated the recognition of AQP4-IgG positive NMOSD (AQP4-NMOSD) as a distinct disease entity (1). Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) were found more recently in a group of patients with demyelinating disease whose clinical features partially overlap with NMOSD and a new disease entity associated with MOG-IgG, called MOG antibody-associated disease (MOGAD), was suggested (2). The clinical phenotypes of MOGAD overlap with those of NMOSD but include a wider range of presenting phenotypes including acute disseminated encephalomyelitis (ADEM), optic neuritis, myelitis, or demyelinating brain lesions; however, its clinical course and prognosis differ from those of AQP4-NMOSD (2,3). > AQP4 is a major water channel protein in the CNS that is highly expressed in the astrocytic foot processes. Complement-dependent AQP4-IgG-mediated cytotoxicity is a major mechanism of astrocyte damage with secondary oligodendrocyte loss, and these lesions are associated with perivascular deposition of activated complements and inflammatory cell infiltration (4). On the other hand, it has not yet been determined how MOG-IgG contributes to MOGAD pathogenesis. MOG is a minor myelin protein predominantly localized at the outermost layer of the myelin sheaths and oligodendrocyte membranes (5).

[12] The Role of Gut Microbiota in Neuromyelitis Optica Spectrum Disorder

• Authors: Shi-Qi Yao, Xiayin Yang, Ling-Ping Cen, Shaoying Tan
• Year: 2024
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/194c7b744b51683530862ea205d9e0f95486c489
• DOI: 10.3390/ijms25063179
• PMID: 38542152
• PMCID: 10970017
• Citations: 10
• Summary: Research on the involvement of the gut microbiota in the pathophysiology of NMOSD and its possible pathogenic mechanisms is summarized, with Clostridium perfringens and Streptococcus confirmed to play a role by multiple studies.
• Evidence snippets:
• Snippet 1 (score: 0.440) > Neuromyelitis optica spectrum disorder (NMOSD) is a rare, disabling inflammatory disease of the central nervous system (CNS). Aquaporin-4 (AQP4)-specific T cells play a key role in the pathogenesis of NMOSD. In addition to immune factors, T cells recognizing the AQP4 epitope showed cross-reactivity with homologous peptide sequences in C. perfringens proteins, suggesting that the gut microbiota plays an integral role in the pathogenicity of NMOSD. In this review, we summarize research on the involvement of the gut microbiota in the pathophysiology of NMOSD and its possible pathogenic mechanisms. Among them, Clostridium perfringens and Streptococcus have been confirmed to play a role by multiple studies. Based on this evidence, metabolites produced by gut microbes, such as short-chain fatty acids (SCFAs), tryptophan (Trp), and bile acid (BA) metabolites, have also been found to affect immune cell metabolism. Therefore, the role of the gut microbiota in the pathophysiology of NMOSD is very important. Alterations in the composition of the gut microbiota can lead to pathological changes and alter the formation of microbiota-derived components and metabolites. It can serve as a biomarker for disease onset and progression and as a potential disease-modifying therapy.

[13] Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study

• Authors: Jeffrey L. Bennett, Kazuo Fujihara, Albert Saiz, A. Traboulsee, Benjamin M Greenberg et al.
• Year: 2025
• Venue: Neurology® Neuroimmunology & Neuroinflammation
• URL: https://www.semanticscholar.org/paper/ddaca7d18b636f7c59a5b26aac620c1e0c5d18ff
• DOI: 10.1212/NXI.0000000000200450
• PMID: 40743487
• PMCID: 12316463
• Citations: 2
• Summary: This study provides Class IV evidence that SAT is safe and effective in patients with NMOSD, supporting SAT as an effective maintenance therapy option for patients with AQP4-IgG+ NMOSD.
• Evidence snippets:
• Snippet 1 (score: 0.437) > Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic, autoimmune disease, characterized by demyelinating lesions in the optic nerves, spinal cord, brainstem, and cerebrum. 1,2 The hallmark clinical manifestations of NMOSD are optic neuritis, resulting in vision loss, and longitudinally extensive transverse myelitis resulting in weakness, sensory impairment, and bladder and bowel dysfunction. 1,3 uaporin-4 immunoglobulin-G-seropositive (AQP4-IgG+) NMOSD generally follows a relapsing disease course, and patients are at persistent risk of relapse regardless of disease duration. 1 Disability and health-related quality-of-life worsening are driven by attacks/relapses, and chronic neurologic disability develops incrementally after attacks. 4 erefore, NMOSD management focuses on the treatment of acute attacks and aims to prevent future relapses, meaning that patients require lifelong preventative therapeutic options that are both safe and effective. 5,6 [9] IL-6, a pleiotropic cytokine implicated in the pathophysiology of AQP4-IgG+ NMOSD, plays a role in the immunopathogenic mechanisms upstream of AQP4-IgG-related effects, mediated through B cell-related and T cell-related pathways. 10,11 IL-6 induces T-cell polarization toward an inflammatory Th17 phenotype, inhibits T regulatory cell development, promotes B-cell differentiation into plasmablasts, and contributes to impaired integrity of the blood-brain barrier, thus enabling pathogenic antibodies and proinflammatory cells to enter the CNS. 10,11 [15][16] In the double-blind (DB) periods of the 2 pivotal phase 3 studies, treatment with SAT in combination with background immunosuppressive therapy (IST) (SAkuraSky) or as a monotherapy (SAkuraStar) significantly reduced relapse risk in adult and adolescent patients with AQP4-IgG+ NMOSD vs placebo (PBO). 13,14

[14] Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico

• Authors: S. Zarei, James Eggert, Laura Franqui-Dominguez, Yonatan Carl, Fernando Boria et al.
• Year: 2018
• Venue: Surgical Neurology International
• URL: https://www.semanticscholar.org/paper/a549c7aa8826272d20c1e908975f5d551622aacc
• DOI: 10.4103/sni.sni_224_18
• PMID: 30603227
• PMCID: 6293609
• Citations: 20
• Influential citations: 2
• Summary: This research will provide a comprehensive overview of all aspects of N MO, including epidemiology, environmental risk factors, genetic factors, molecular mechanism, symptoms, comorbidities and clinical differentiation, diagnosis, treatment, its management, and prognosis, and evaluate the demographic features and clinical phenotype of NMO patients in PR.
• Evidence snippets:
• Snippet 1 (score: 0.436) > Neuromyelitis optica (NMO) is an immune-mediated inflammatory disorder of the central nervous system. It is characterized by concurrent inflammation and demyelination of the optic nerve (optic neuritis [ON]) and the spinal cord (myelitis). Multiple studies show variations in prevalence, clinical, and demographic features of NMO among different populations. In addition, ethnicity and race are known as important factors on disease phenotype and clinical outcomes. There are little data on information about NMO patients in underserved groups, including Puerto Rico (PR). In this research, we will provide a comprehensive overview of all aspects of NMO, including epidemiology, environmental risk factors, genetic factors, molecular mechanism, symptoms, comorbidities and clinical differentiation, diagnosis, treatment, its management, and prognosis. We will also evaluate the demographic features and clinical phenotype of NMO patients in PR. This will provide a better understanding of NMO and establish a basis of knowledge that can be used to improve care. Furthermore, this type of population-based study can distinguish the clinical features variation among NMO patients and will provide insight into the potential mechanisms that cause these variations.

[15] Neuromyelitis Optica Spectrum Disorders: Clinical Perspectives, Molecular Mechanisms, and Treatments

• Authors: Subramanian Thangaleela, B. Sivamaruthi, A. Radha, P. Kesika, C. Chaiyasut
• Year: 2023
• Venue: Applied Sciences
• URL: https://www.semanticscholar.org/paper/c4ea13835c99020313ed6eda722e17420e6ab657
• DOI: 10.3390/app13085029
• Citations: 8
• Summary: All possible recent studies related to molecular mechanisms, clinical perspectives, and treatment methodologies of the disease are provided, particularly focusing on recent developments in clinical criteria and therapeutic formulations.
• Evidence snippets:
• Snippet 1 (score: 0.436) > Neuromyelitis optica (NMO) is a rare autoimmune inflammatory disorder affecting the central nervous system (CNS), specifically the optic nerve and the spinal cord, with severe clinical manifestations, including optic neuritis (ON) and transverse myelitis. Initially, NMO was wrongly understood as a condition related to multiple sclerosis (MS), due to a few similar clinical and radiological features, until the discovery of the AQP4 antibody (NMO-IgG/AQP4-ab). Various etiological factors, such as genetic-environmental factors, medication, low levels of vitamins, and others, contribute to the initiation of NMO pathogenesis. The autoantibodies against AQP4 target the AQP4 channel at the blood–brain barrier (BBB) of the astrocyte end feet, which leads to high permeability or leakage of the BBB that causes more influx of AQP4-antibodies into the cerebrospinal fluid (CSF) of NMO patients. The binding of AQP4-IgG onto the AQP4 extracellular epitopes initiates astrocyte damage through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Thus, a membrane attack complex is formed due to complement cascade activation; the membrane attack complex targets the AQP4 channels in the astrocytes, leading to astrocyte cell damage, demyelination of neurons and oligodendrocytes, and neuroinflammation. The treatment of NMOSD could improve relapse symptoms, restore neurological functions, and alleviate immunosuppression. Corticosteroids, apheresis therapies, immunosuppressive drugs, and B cell inactivating and complement cascade blocking agents have been used to treat NMOSD. This review intends to provide all possible recent studies related to molecular mechanisms, clinical perspectives, and treatment methodologies of the disease, particularly focusing on recent developments in clinical criteria and therapeutic formulations.

[16] Neuroprotective therapies for multiple sclerosis and other demyelinating diseases

• Authors: P. Villoslada
• Year: 2016
• Venue: Multiple Sclerosis and Demyelinating Disorders
• URL: https://www.semanticscholar.org/paper/18513effd17c9ab745065eafc95282d00453ffa8
• DOI: 10.1186/s40893-016-0004-0
• Citations: 33
• Influential citations: 1
• Summary: Improvement in the understanding of underlying biology, in the design of clinical trials specific for assessing neuroprotection, and new technologies for developing novel therapies for neuroprotection suggest a new avenue for treating MS, Optic Neuritis or Neuromyelitis Optica.
• Evidence snippets:
• Snippet 1 (score: 0.431) > Damage to the Central Nervous Systems (CNS) in Multiple Sclerosis (MS) seems to be mainly due to chronic inflammation of the CNS with superimposed bouts of inflammatory activity by the adaptive immune system. The immune mediated damage can be amplified by neurodegenerative mechanisms in damaged axons including anterograde or retrograde axonal or transynaptic degeneration, synaptic pruning and neuronal or oligodendrocyte death. As such, it is highly unlikely that CNS damage can be prevented using only immunomodulatory drugs. For this reason, neuroprotection, aimed at preventing axonal, neuronal, myelin, and oligodendrocyte damage and cell death in the presence of this toxic microenvironment is highly pursued in MS and other demyelinating diseases. Neuroprotective strategies target different processes including oxidative stress, ionic imbalance (sodium, potassium or calcium), energy depletion, trophic factor support, metabolites balance, excitotoxicity, apoptosis, remyelination, etc. Although none of these strategies have translated into approved drugs to date, improvement in the understanding of underlying biology, in the design of clinical trials specific for assessing neuroprotection, and new technologies for developing novel therapies for neuroprotection suggest a new avenue for treating MS, Optic Neuritis or Neuromyelitis Optica (NMO). Several of these therapies are now entering clinical phases and if successful, such strategies would improve patients’ quality of life, and will be even more critical for patients with progressive MS. In the event that such therapies target natural repair mechanisms rather than disease specific processes, they can potentially be useful for other brain diseases such as stroke, neurodegenerative diseases, brain trauma or epilepsy.

[17] Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica

• Authors: Tianjiao Duan, Alex J. Smith, A. Verkman
• Year: 2018
• Venue: Journal of Neuroinflammation
• URL: https://www.semanticscholar.org/paper/ac8bc8f4ff0f66b966e404f0e008f7e8fbc138e7
• DOI: 10.1186/s12974-018-1333-z
• PMID: 30348195
• PMCID: 6198534
• Citations: 70
• Influential citations: 1
• Summary: The hypothesis that complement bystander injury, which involves diffusion to nearby cells of activated soluble complement components from complement-injured astrocytes, is a general phenomenon that may contribute to neuronal injury in NMO is tested and evidence that complement bystanderser injury may be ageneral phenomenon for brain cell injury following AQP4-IgG-targeted astroCyte death is provided.
• Evidence snippets:
• Snippet 1 (score: 0.430) > Aquaporin-4-immunoglobulin G (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (herein called NMO) is an autoimmune demyelinating disease of the central nervous system. NMO pathogenesis involves binding of AQP4-IgG autoantibodies to water channel AQP4 on astrocytes, resulting in complement-and cell-mediated astrocyte injury, inflammation, demyelination, and neuron loss [1][2][3]. Though demyelination and neuronal injury could be secondary consequences of astrocyte death and an inflammatory response, the rapid disease progression seen in some NMO patients [4,5] and the rapid pathological changes seen in animal models during in vivo imaging of lesion formation [6,7] suggest more direct mechanisms by which astrocyte injury produces neuronal injury and neurologic deficit. Several mechanisms have been proposed to account for neuronal injury in NMO, including excitotoxic damage following glutamate release from injured astrocytes [8,9] and secondary recruitment of granulocytes and cytotoxic T cells [10,11]. However, the role of excitotoxic mechanisms has been controversial [12,13], and although cellular mechanisms are probably important, they are unlikely to cause the immediate damage to surrounding cells following exposure to AQP4-IgG. > Complement activation is a major effector pathway in NMO. NMO pathology in humans shows centrovascular deposition of activated complement [14][15][16], and early clinical trials data support the efficacy of a complement inhibitor [17,18]. Complement-dependent NMO pathology is also seen in experimental animal models of NMO produced by passive transfer of AQP4-IgG [6,7,19]. We recently reported evidence for complement bystander injury to oligodendrocytes, in which complement activation following AQP4-IgG binding to AQP4 on astrocytes results in killing of nearby oligodendrocytes by a bystander mechanism involving local diffusion of activated, soluble complement components, leading to formation of the complement membrane attack complex (MAC

[18] Long-term Effects of IL-6 Receptor Blockade Therapy on Regulatory Lymphocytes and Neutrophils in Neuromyelitis Optica Spectrum Disorder

• Authors: T. Matsuoka, Manabu Araki, Youwei Lin, Tomoko Okamoto, Ralf Gold et al.
• Year: 2023
• Venue: Neurology® Neuroimmunology & Neuroinflammation
• URL: https://www.semanticscholar.org/paper/e1a506662cdf3585a5ab657ba30d687f27edf8d3
• DOI: 10.1212/NXI.0000000000200173
• PMID: 37863660
• PMCID: 10691226
• Citations: 14
• Summary: In patients with active NMOSD not treated with molecular targeting drugs, reduction or deficiency in lymphocytes with regulatory potentials and activation of neutrophils is observed, however, introduction of anti–IL-6R therapy accompanied by tapering concomitant drugs corrected such abnormalities, which might contribute to persistent relapse prevention.
• Evidence snippets:
• Snippet 1 (score: 0.430) > Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the CNS, causing inflammatory damage to the optic nerve, spinal cord, brainstem, and the cerebral white matter. 1,2 Anti-aquaporin 4-antibody (AQP4-Ab) 1,3,4 is a surrogate marker for a core group of NMOSD with predominant astrocyte pathology. For such anti-AQP4-Ab-positive patients, disease-modifying drugs for multiple sclerosis (MS), such as interferon β, are not efficacious but rather harmful, [5][6][7] indicating the difference between NMOSD and MS in the immunopathogenesis. Until recently, corticosteroids and off-label immunosuppressive drugs or plasmapheresis were the only available treatment options for NMOSD. However, clinical trials based on the pathophysiology of NMOSD have provided several high-efficacy drugs, including the B-cell depleting drugs rituximab 8,9 and inebilizumab, 10 the anticomplement C5 drug eculizumab, 11 and the anti-IL-6R drug satralizumab. 12,13 Currently, the mechanism of action of each drug in vivo remains poorly understood, and no theoretical background is offered to select a drug for each patient. > This study was initiated before the approval of such drugs. 5][16][17] Recent phase 3 clinical trials revealed that the recycling anti-IL-6R monoclonal antibody satralizumab as add-on therapy 12 or as monotherapy 13 would significantly reduce relapses in anti-AQP4-Ab-positive NMOSD. However, because IL-6 is a pleiotropic cytokine involved in numerous biological responses, the mechanisms of IL-6R blockade therapy remain to be investigated further, particularly regarding the cellular immune profiling pretherapy and posttherapy, to clarify the important features of the therapy in comparison with other approved drugs.

[19] Abstracts

• Authors: N. Turner, Schmid, L. Mahon
• Year: 1917
• Venue: ASN NEURO
• URL: https://www.semanticscholar.org/paper/ac7be82f67b14aa621f838b8a8d56012eb36d038
• DOI: 10.2337/diab.14.12.814
• PMCID: 9720786
• Summary: Results indicated that after intravenous sodium tolbutamide in duodenal ulcer subjects there was an increase in gastric secretion of acid, chloride, and potassium, as well as in volume of secretion, similar to, but milder than, those producible in reported studies utilizing insulin.
• Evidence snippets:
• Snippet 1 (score: 0.430) > The Astrocytes Role, Linking Basic Research, Clinical Characteristics, and Therapeutic Perspectives Violeta Millet 1,2,3 > Neuromyelitis Optica spectrum disorder (NMOSD), previously known as Devic Disease, is a chronic autoimmune inflammatory disease of the central nervous system characterized by secondary immune-mediated demyelination and consequent axonal damage. NMOSD clinically preferentially affects the optic nerves (optic neuritis) and the spinal cord (transverse myelitis). An important advance in understanding neuromyelitis Optica (NMO) pathogenesis was the discovery of the AQP-4 antibody that targets the water channel membrane protein aquaporin-4 (AQP-4). AQP-4 is expressed on the end-feet membranes of astrocytes along the blood-brain barrier of astrocytes, in ependymal cell membranes, and in Muller cells present on the fovea in the retina. Serum Aqp4 antibodies existed in approximately 80-90% of patients with NMO and more than half of patients with NMOSD. The binding of AQP-4-IgG to AQP-4 causes complementdependent cytotoxicity, antibody-dependent cellular cytotoxicity, and the consequent astrocyte injury. Animal models allow us to understand the pathogenic mechanisms in the immune cascade and help the development of potential drug therapies. Diverse in vivo, ex vivo, and in vitro experimental systems have been used but an ideal animal model of NMO with spontaneous AQP-4-IGG positive optic neuritis and transverse myelitis has yet to be created. Large research is in progress on the pathogenesis, genetic background, serum biomarkers, and optic coherence tomography segmentation. Novel drugs targeting the complement cascade system, IL-6R, and B cells are being studied. Recently, novel therapeutic strategies focused on the induction of antigen-specific immune tolerance by administrating tolerogenic immune-modifying nanoparticles are being developed. Deep research in immune tolerance-based therapies in NMO is likely to be a major step toward improving the treatment outcomes of the disease. In many retina degenerative diseases, the progressive

[20] Optic neuritis in demyelinating diseases: study of 38 cases

• Authors: J. Ferreira, Cristiane Rebello Gomes de Souza Fontes, Carolina do Val Ferreira Ramos, O. Nascimento
• Year: 2023
• Venue: Arquivos de Neuro-Psiquiatria
• URL: https://www.semanticscholar.org/paper/5e9a36468c07948b8f617b71839ac9992ece204c
• DOI: 10.1055/s-0044-1792093
• PMID: 39675357
• PMCID: 11646668
• Citations: 1
• Summary: Patients with optic neuritis as the initial symptom were predominantly female, aged between 21 and 40 years, and of predominantly white ethnicity, with a higher prevalence of MS and a direct relationship between the healthcare sector and the time to diagnosis became evident.
• Evidence snippets:
• Snippet 1 (score: 0.429) > A growing area of study with notable development recently has been neuroimmunology, both in terms of diagnostic methods and treatments. The main clinical disorders involved in this area of neurology are multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG)-associated disorders (MOGADs). ][3][4] Characterized by their autoimmune etiology, demyelinating diseases (DDs) exhibit in their pathophysiology an attack to the myelin sheath, the substance that covers the axons in the central nervous system. This condition, exemplified by multiple sclerosis (MS), transverse myelitis, leukodystrophies and optic neuritis (ON), presents a wide range of clinical manifestations and temporal profiles of development, including the possibility of relapses. 5 ptic neuritis, an inflammation of the optic nerve, can be caused by various factors, including genetic aspects (a strong association with the HLA-DRB1 and HLA-B27 genes), external influences (trauma and/or toxins), and the activation of a cross-immune response to infections, which is the main mechanism. 6,7 egarding the activation mechanism of the cross-immune response, it can occur with the reaction of serological markers of the type immunoglobulin G (IgG), including MOG-IgG, which targets the MOG glycoprotein in the myelin present in oligodendrocytes. Another influential immunoglobulin in the process is NMO-IgG, which reacts against the aquaporin-4 present in astrocytic cells. 5,7 epending on the stimulus response to the neuronal structuring cells and the impairment of propagation of the nerve impulse from the retina to the lateral geniculate bodies, the possibility of visual impairments arises, presenting with the most typical symptoms of ON: ocular pain on movement with acute loss of unilateral visual acuity.

Notes

• This provider combines search_papers_by_relevance with snippet_search.
• No synthesis or second-stage model call is performed.

Disorder

• Name: Neuromyelitis Optica
• Category: Neurological Disorder
• Existing deep-research providers: falcon, perplexity
• Existing evidence reference count in YAML: 28

Key Pathophysiology Nodes

• AQP4-IgG-Mediated Astrocyte Injury
• AQP4 Endocytosis and Complement-Independent Cytotoxicity
• Deep research literature mapping

Citation Inventory (for evidence mapping)

• DOI:10.1007/s00415-023-11910-z
• DOI:10.1038/s41598-024-53661-5
• DOI:10.1096/fj.09-141978
• DOI:10.1111/1756-185x.14973
• DOI:10.1111/cen3.70019
• DOI:10.1126/sciadv.adq7560
• DOI:10.1172/jci141694
• DOI:10.1177/17562864251357393
• DOI:10.1186/s41232-023-00291-5
• DOI:10.1212/nxi.0000000000000343
• DOI:10.1212/nxi.0000000000000727
• DOI:10.1212/wnl.0000000000201465
• DOI:10.3389/fimmu.2022.959469
• DOI:10.3389/fimmu.2024.1320094
• DOI:10.3389/fimmu.2025.1635989
• DOI:10.3389/fneur.2017.00062
• DOI:10.3390/ijms25063179
• DOI:10.3390/ijms251910625
• PMID:26656646

Disease Pathophysiology Research Report

Target Disease - Disease Name: Neuromyelitis Optica Spectrum Disorder (NMOSD; AQP4-IgG–positive form emphasized) - MONDO ID: — - Category: Neurological Disorder

Pathophysiology description NMOSD is a primary autoimmune astrocytopathy driven in most patients by pathogenic IgG1 autoantibodies against the water channel aquaporin-4 (AQP4) concentrated on astrocyte endfeet at the blood–brain barrier (BBB). Binding of AQP4-IgG to AQP4 orthogonal arrays of particles on astrocytes activates the classical complement pathway, culminating in C5b-9 membrane attack complex (MAC)–mediated astrocyte injury with secondary demyelination and axonal damage; antibody-dependent cellular cytotoxicity (ADCC) may also contribute (Kinoshita & Okuno, 2023; NEMOS 2024) (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, kumpfel2024updateonthe pages 1-2). Complement split products (notably C5a) recruit and activate neutrophils, which are key effectors of early BBB disruption and lesion expansion; pharmacologic C5aR blockade attenuates astrocyte loss in vivo, underscoring this pathway (Winkler et al., 2021) (winkler2021bloodbrainbarrierresealing pages 1-2, winkler2021bloodbrainbarrierresealing pages 11-12). IL-6/Th17-axis signaling is integrally linked: ex vivo, AQP4-IgG/AQP4 immune complexes together with complement elicit IL-6 and IL-17A release from patient PBMCs, “prompt[ing] a Th17-biased response” (Nishiyama et al., 2024) (nishiyama2024antiaquaporin4immunecomplex pages 1-2). BBB dysfunction helps initiate CNS access for circulating AQP4-IgG and complement; neutrophils drive structural BBB breakdown, and autoantibodies to endothelial GRP78 have been implicated in BBB impairment, while astrocyte-derived IL-6 further increases permeability (Winkler et al., 2021; Shimizu & Nakamori, 2024) (winkler2021bloodbrainbarrierresealing pages 1-2, shimizu2024blood–brainbarrierdisruption pages 9-10). Peripheral priming may involve gut microbiota molecular mimicry: AQP4-specific T cells cross-react with homologous peptides from Clostridium perfringens, supporting a gut-brain axis in NMOSD (Yao et al., 2024) (yao2024theroleof pages 5-6).

Recent developments and latest research (2023–2024 prioritized) - Mechanistic immunology: Complement-dependent induction of Th17 cytokines by AQP4-IgG/AQP4 immune complexes with complement (Nishiyama et al., 2024) (nishiyama2024antiaquaporin4immunecomplex pages 1-2). 2024 NEMOS recommendations reaffirm AQP4-IgG as a pathogenic driver and highlight approved targeted agents (Kümpfel et al., 2024) (kumpfel2024updateonthe pages 1-2). - BBB biology: Newer reviews emphasize IL-6’s role in BBB permeability and the contribution of GRP78 autoantibodies to BBB dysfunction in NMOSD (Shimizu & Nakamori, 2024) (shimizu2024blood–brainbarrierdisruption pages 9-10). - Microbiome: Molecular mimicry with C. perfringens peptides driving AQP4-reactive Th17 responses is synthesized in 2024 evidence (Yao et al., 2024) (yao2024theroleof pages 5-6). - Complement patterns distinguishing NMOSD vs MOGAD: During attacks, AQP4+ NMOSD shows higher sC5b-9 (terminal complement complex) than MOGAD, whereas MOGAD exhibits greater upstream C3 degradation products (iC3b) and regulators (C1-INH, factor H), pointing to distinct complement biology (Cho et al., 2024) (cho2024differentiatedpatternof pages 6-9).

Current applications and real-world implementations - Approved targeted therapies derive directly from mechanistic pathways: complement C5 inhibitors (eculizumab, ravulizumab), anti-CD19 B-cell depletion (inebilizumab), and IL-6 receptor blockade (satralizumab) reduce relapses in AQP4-IgG+ NMOSD—now embedded in consensus recommendations (Kümpfel et al., 2024) (kumpfel2024updateonthe pages 1-2). Mechanistic alignment: C5 blockade interrupts MAC formation and C5a chemotaxis; B-cell depletion reduces AQP4-IgG–secreting plasmablasts; IL-6R blockade dampens plasmablast survival and Th17 polarization (Nishiyama et al., 2024; Kinoshita & Okuno, 2023) (nishiyama2024antiaquaporin4immunecomplex pages 1-2, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5). Clinical impact reported includes marked relapse risk reductions with C5 inhibitors (Nishiyama et al., 2024) (nishiyama2024antiaquaporin4immunecomplex pages 1-2).

Expert opinions and analysis (authoritative sources) - 2024 NEMOS consensus emphasizes NMOSD as a severe astrocytopathy in which perivascular deposition of IgG and complement (C9neo) with granulocyte infiltrates is typical; management pivots on rapid attack therapy and long-term relapse prevention with targeted biologics (Kümpfel et al., 2024) (kumpfel2024updateonthe pages 1-2). - Translational studies indicate neutrophils are principal BBB disruptors early in lesion formation, and C5a–C5aR1 signaling is a tractable target (Winkler et al., 2021) (winkler2021bloodbrainbarrierresealing pages 1-2, winkler2021bloodbrainbarrierresealing pages 11-12).

Relevant statistics and biomarker data (recent studies) - Complement activation biomarkers: sC5b-9 is elevated during AQP4+ NMOSD attacks compared with MOGAD, while MOGAD shows higher iC3b and complement regulators (Cho et al., 2024) (cho2024differentiatedpatternof pages 6-9). - Fluid biomarkers of injury and permeability: Albumin quotient (Qalb) rises during BBB breakdown; serum/CSF GFAP and NfL increase transiently during attacks and correlate with disability and relapse activity; IL-6 is elevated in CSF/serum and associates with disease activity (Shimizu & Nakamori, 2024) (shimizu2024blood–brainbarrierdisruption pages 9-10). - Therapeutic effect sizes: C5 inhibition produced large reductions in relapse risk in clinical development (e.g., eculizumab/“PREVENT”, ravulizumab programs) summarized alongside mechanistic rationale (Nishiyama et al., 2024; NEMOS 2024) (nishiyama2024antiaquaporin4immunecomplex pages 1-2, kumpfel2024updateonthe pages 1-2).

Core Pathophysiology Primary mechanisms - AQP4-IgG–mediated astrocytopathy with complement activation (classical pathway via C1q, culminating in MAC) leading to astrocyte loss and secondary demyelination; ADCC likely contributes (Kinoshita & Okuno, 2023; NEMOS 2024) (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, kumpfel2024updateonthe pages 1-2). - C5a-driven recruitment/activation of neutrophils; neutrophil proteases and MMPs disrupt BBB; C5aR blockade reduces lesion burden (Winkler et al., 2021) (winkler2021bloodbrainbarrierresealing pages 1-2, winkler2021bloodbrainbarrierresealing pages 11-12). - IL-6/Th17 axis engagement: complement-dependent AQP4 immune complexes induce IL-6 and IL-17A, promoting Th17-biased inflammation (Nishiyama et al., 2024) (nishiyama2024antiaquaporin4immunecomplex pages 1-2). - BBB disruption as an initiating and amplifying step; endothelial-targeted autoantibodies (GRP78) and IL-6 increase permeability (Shimizu & Nakamori, 2024; Winkler et al., 2021) (shimizu2024blood–brainbarrierdisruption pages 9-10, winkler2021bloodbrainbarrierresealing pages 1-2). - Peripheral priming by microbiota molecular mimicry—AQP4 epitope homology in C. perfringens and Th17 responses (Yao et al., 2024) (yao2024theroleof pages 5-6).

Dysregulated pathways - Complement cascade (C1q→C3→C5→C5b-9), chemokines/cytokines (IL-6, IL-17A, CXCL10, CXCL13, CCL2), NF-κB stress signaling in astrocytes/microglia (Kinoshita & Okuno, 2023; Nishiyama et al., 2024; NEMOS 2024) (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, nishiyama2024antiaquaporin4immunecomplex pages 1-2, kumpfel2024updateonthe pages 1-2).

Affected cellular processes - Complement-dependent cytotoxicity, ADCC against astrocytes; neutrophil degranulation/NETosis; microglial activation via complement receptors; Th17 differentiation and cytokine release; BBB tight-junction disruption (Winkler et al., 2021; Kinoshita & Okuno, 2023; Nishiyama et al., 2024) (winkler2021bloodbrainbarrierresealing pages 1-2, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, nishiyama2024antiaquaporin4immunecomplex pages 1-2).

Key Molecular Players - Genes/Proteins: AQP4 (HGNC:AQP4), Complement C1q (HGNC:C1QA/B/C), C3 (HGNC:C3), C5/C5a (HGNC:C5), MAC/C5b-9; cytokines/chemokines IL-6 (HGNC:IL6), IL-17A (HGNC:IL17A), CXCL10 (HGNC:CXCL10), CXCL13 (HGNC:CXCL13), CCL2 (HGNC:CCL2); stress/inflammatory mediator CHI3L1 (HGNC:CHI3L1) (Kinoshita & Okuno, 2023; Nishiyama et al., 2024; NEMOS 2024) (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, nishiyama2024antiaquaporin4immunecomplex pages 1-2, kumpfel2024updateonthe pages 1-2). - Chemical entities: ATP (danger signal; CHEBI:ATP), sC5b-9 (terminal complement complex) (Kinoshita & Okuno, 2023; Cho et al., 2024) (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, cho2024differentiatedpatternof pages 6-9). - Cell types: Astrocytes (CL:astrocyte; primary target), B cells/plasmablasts (AQP4-IgG source), neutrophils and eosinophils (granulocyte effectors), microglia (innate amplification), Th17 CD4+ T cells (effector lineage) (Kinoshita & Okuno, 2023; Winkler et al., 2021; Nishiyama et al., 2024; NEMOS 2024) (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, winkler2021bloodbrainbarrierresealing pages 1-2, nishiyama2024antiaquaporin4immunecomplex pages 1-2, kumpfel2024updateonthe pages 1-2). - Anatomical locations: Optic nerve, spinal cord (longitudinally extensive transverse myelitis), area postrema and hypothalamus—sites with characteristic lesion patterns (NEMOS 2024; Kinoshita & Okuno, 2023) (kumpfel2024updateonthe pages 1-2, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5).

Biological Processes (GO-like annotation) - Complement-dependent cytotoxicity (GO:complement-dependent cytotoxicity) against astrocytes (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, kumpfel2024updateonthe pages 1-2). - Antibody-dependent cellular cytotoxicity (GO:antibody-dependent cellular cytotoxicity) (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5). - NF-κB signaling (GO:NF-kappaB signaling) upregulated in antibody/complement-stressed astrocytes (nishiyama2024antiaquaporin4immunecomplex pages 1-2). - Th17 cell differentiation (GO:Th17 cell differentiation) driven by IL-6 and complement signals (nishiyama2024antiaquaporin4immunecomplex pages 1-2). - Blood–brain barrier disruption (GO:blood–brain barrier disruption) mediated by neutrophils and inflammatory mediators (winkler2021bloodbrainbarrierresealing pages 1-2, shimizu2024blood–brainbarrierdisruption pages 9-10).

Cellular Components - Astrocyte plasma membrane/endfeet, perivascular space; complement deposition (C1q, C3 fragments) and terminal MAC on astrocyte membranes; extracellular space enriched in cytokines/chemokines (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, kumpfel2024updateonthe pages 1-2).

Disease Progression (sequence of events) 1) Peripheral priming: gut microbial mimicry primes AQP4-reactive T cells (C. perfringens epitope homology) and Th17 bias (Yao et al., 2024) (yao2024theroleof pages 5-6). 2) BBB entry: pre-existing inflammation and BBB loosening (neutrophil-mediated, IL-6–driven, GRP78 autoantibodies) allow serum AQP4-IgG and complement into the CNS (Winkler et al., 2021; Shimizu & Nakamori, 2024) (winkler2021bloodbrainbarrierresealing pages 1-2, shimizu2024blood–brainbarrierdisruption pages 9-10). 3) Astrocyte injury: AQP4-IgG binds AQP4, fixes complement (C1q→C5b-9), triggers astrocyte lysis and ADCC (Kinoshita & Okuno, 2023; NEMOS 2024) (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, kumpfel2024updateonthe pages 1-2). 4) Innate amplification: C5a recruits neutrophils; microglia are activated by complement fragments and danger signals (ATP), amplifying inflammation and BBB damage (Winkler et al., 2021; Kinoshita & Okuno, 2023) (winkler2021bloodbrainbarrierresealing pages 1-2, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5). 5) Secondary tissue loss: oligodendrocyte/myelin injury and axonal dysfunction accrue downstream of astrocytopathy (NEMOS 2024) (kumpfel2024updateonthe pages 1-2).

Phenotypic Manifestations and Imaging Features - Clinical phenotypes tightly map to astrocyte-rich regions: severe optic neuritis, longitudinally extensive transverse myelitis (central cord gray), area postrema syndrome (intractable vomiting/hiccups), and hypothalamic lesions; perivascular complement deposition and granulocyte infiltrates are typical (Kümpfel et al., 2024; Kinoshita & Okuno, 2023) (kumpfel2024updateonthe pages 1-2, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5). - Distinguishing from MOGAD/MS: AQP4+ NMOSD shows higher terminal pathway activity (sC5b-9) than MOGAD, which exhibits more upstream C3 degradation (iC3b)/regulatory signatures; clinical/MRI distribution differs from MS and MOGAD (Cho et al., 2024; NEMOS 2024) (cho2024differentiatedpatternof pages 6-9, kumpfel2024updateonthe pages 1-2).

Evidence quotes (selected) - “Co-stimulation of PBMCs with AQP4-IgG/AQP4 immunocomplex and complement prompts a Th17-biased response” (Nishiyama et al., 2024) (nishiyama2024antiaquaporin4immunecomplex pages 1-2). - In experimental NMOSD, “polymorphonuclear leukocytes (PMNs) are the main mediators of BBB disruption,” and C5aR antagonism reduced astrocyte loss (Winkler et al., 2021) (winkler2021bloodbrainbarrierresealing pages 1-2, winkler2021bloodbrainbarrierresealing pages 11-12).

Gene/Protein annotations with ontology terms (HGNC, GO) - AQP4 (HGNC:AQP4): antigenic target; processes—complement-dependent cytotoxicity; cellular component—astrocyte endfeet (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, kumpfel2024updateonthe pages 1-2). - IL6 (HGNC:IL6): promotes plasmablast survival and Th17 polarization; processes—Th17 differentiation, BBB permeability (nishiyama2024antiaquaporin4immunecomplex pages 1-2, shimizu2024blood–brainbarrierdisruption pages 9-10). - IL17A (HGNC:IL17A): effector cytokine of Th17; processes—neuroinflammation amplification (nishiyama2024antiaquaporin4immunecomplex pages 1-2). - C1q (HGNC:C1QA/B/C), C3 (HGNC:C3), C5 (HGNC:C5): complement activation cascade culminating in MAC (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, winkler2021bloodbrainbarrierresealing pages 11-12, kumpfel2024updateonthe pages 1-2). - CXCL10 (HGNC:CXCL10), CXCL13 (HGNC:CXCL13), CCL2 (HGNC:CCL2): chemoattractants for T and B cells and myeloid cells (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, kumpfel2024updateonthe pages 1-2).

Phenotype associations (HP terms) - Optic neuritis (HP term) and longitudinally extensive transverse myelitis; area postrema syndrome (intractable vomiting/hiccups)—clinical correlates of astrocytopathy (Kümpfel et al., 2024) (kumpfel2024updateonthe pages 1-2).

Cell type involvement (CL terms) - CL:astrocyte; CL:neutrophil; CL:eosinophil; CL:B cell/CL:plasmablast; CL:CD4+ Th17 T cell; CL:microglial cell (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, winkler2021bloodbrainbarrierresealing pages 1-2, nishiyama2024antiaquaporin4immunecomplex pages 1-2, kumpfel2024updateonthe pages 1-2).

Anatomical locations (UBERON terms) - UBERON:optic nerve; UBERON:spinal cord; UBERON:area postrema; UBERON:hypothalamus; UBERON:blood–brain barrier (kumpfel2024updateonthe pages 1-2, winkler2021bloodbrainbarrierresealing pages 1-2, shimizu2024blood–brainbarrierdisruption pages 9-10).

Chemical entities (CHEBI terms) - CHEBI:ATP (danger signal); terminal complement complex (sC5b-9) as a biomarker of complement activation (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, cho2024differentiatedpatternof pages 6-9).

Mechanism-informed therapies (rationale with data) - Complement C5 inhibitors (eculizumab, ravulizumab): block C5 cleavage to prevent C5a chemotaxis and MAC formation; associated with large relapse risk reductions in AQP4+ NMOSD (Nishiyama et al., 2024; NEMOS 2024) (nishiyama2024antiaquaporin4immunecomplex pages 1-2, kumpfel2024updateonthe pages 1-2). - B-cell depletion (inebilizumab): targets CD19 lineage including plasmablasts producing AQP4-IgG; reduces relapse risk (NEMOS 2024) (kumpfel2024updateonthe pages 1-2). - IL-6R blockade (satralizumab): interrupts IL-6–dependent plasmablast survival and Th17 polarization; reduces relapses (NEMOS 2024; Nishiyama et al., 2024) (kumpfel2024updateonthe pages 1-2, nishiyama2024antiaquaporin4immunecomplex pages 1-2).

Embedded structured summary (ontology-mapped) | Entity | Type | Ontology (ID system) | Role in NMOSD pathophysiology (one sentence) | Key evidence | URL / Year | |---|---|---:|---|---|---| | AQP4 | Gene/Protein | HGNC:AQP4 | Water-channel on astrocyte endfeet and primary antigenic target; AQP4-IgG binding triggers complement activation and astrocyte lysis. | (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, kumpfel2024updateonthe pages 1-2) | https://doi.org/10.1186/s41232-023-00291-5 (2023) | | IL6 | Cytokine | HGNC:IL6 | Pro-inflammatory cytokine elevated in serum/CSF during attacks; promotes plasmablast survival and Th17 polarization. | (nishiyama2024antiaquaporin4immunecomplex pages 1-2, correale2025inductionofimmune pages 3-4) | https://doi.org/10.1038/s41598-024-53661-5 (2024) | | IL17A | Cytokine | HGNC:IL17A | Effector Th17 cytokine contributing to CNS inflammation downstream of complement-dependent stimulation. | (nishiyama2024antiaquaporin4immunecomplex pages 1-2) | https://doi.org/10.1038/s41598-024-53661-5 (2024) | | CXCL10 | Cytokine/Chemokine | HGNC:CXCL10 | IFN-inducible chemokine raised in peripheral/lesional signatures that recruits T cells and associates with inflammatory signaling. | (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, kumpfel2024updateonthe pages 1-2) | https://doi.org/10.1007/s00415-023-11910-z (2024) | | CXCL13 | Chemokine | HGNC:CXCL13 | B-cell/Tfh chemokine elevated in AQP4-NMOSD serum proteomics, indicating B-cell follicular activity. | (kumpfel2024updateonthe pages 1-2) | https://doi.org/10.1007/s00415-023-11910-z (2024) | | CCL2 | Chemokine | HGNC:CCL2 | Astrocyte-derived chemoattractant that amplifies leukocyte recruitment and astrocyte injury in AQP4-IgG contexts. | (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, nishiyama2024antiaquaporin4immunecomplex pages 1-2) | https://doi.org/10.1186/s41232-023-00291-5 (2023) | | CHI3L1 | Protein (chitinase-like) | HGNC:CHI3L1 | Astrocyte-intrinsic inflammatory amplifier implicated in promoting demyelination and upregulating complement/cytokine responses. | (nishiyama2024antiaquaporin4immunecomplex pages 1-2, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5) | https://doi.org/10.1038/s41598-024-53661-5 (2024) | | Complement C1q | Complement component | HGNC:C1QA/C1QB/C1QC | Classical pathway initiator that binds immune complexes and promotes downstream complement cascade activation in lesions. | (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, kumpfel2024updateonthe pages 1-2) | https://doi.org/10.1186/s41232-023-00291-5 (2023) | | Complement C3 | Complement component | HGNC:C3 | Central complement protein whose cleavage/amplification (iC3b etc.) marks complement activation and opsonization in NMOSD. | (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, nishiyama2024antiaquaporin4immunecomplex pages 1-2) | https://doi.org/10.1186/s41232-023-00291-5 (2023) | | Complement C5 / C5a | Complement component (anaphylatoxin) | HGNC:C5 | Terminal pathway mediator; C5a is a potent chemoattractant driving neutrophil recruitment and inflammation. | (winkler2021bloodbrainbarrierresealing pages 1-2, winkler2021bloodbrainbarrierresealing pages 11-12) | https://doi.org/10.1172/jci141694 (2021) | | C5b-9 (MAC) | Complement complex | (Terminal complement complex / MAC) | Forms the membrane attack complex that causes astrocyte membrane damage and contributes to astrocytolysis. | (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, kumpfel2024updateonthe pages 1-2) | https://doi.org/10.1186/s41232-023-00291-5 (2023) | | Microglia | Cell type | CL:microglial cell | CNS-resident innate immune cells activated by astrocyte injury and complement fragments (C3a/C5a), amplifying local inflammation. | (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, winkler2021bloodbrainbarrierresealing pages 1-2) | https://doi.org/10.1172/jci141694 (2021) | | Neutrophils / NETs | Cell type / process | CL:neutrophil; GO:neutrophil extracellular trap formation | Early infiltrating granulocytes that contribute proteases, NETs and BBB disruption and are recruited by C5a and astrocyte-derived chemokines. | (winkler2021bloodbrainbarrierresealing pages 1-2, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, nishiyama2024antiaquaporin4immunecomplex pages 1-2) | https://doi.org/10.1172/jci141694 (2021) | | Eosinophils | Cell type | CL:eosinophil | Granulocytes found in perivascular NMOSD lesions that participate in inflammatory tissue damage alongside neutrophils. | (kumpfel2024updateonthe pages 1-2, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5) | https://doi.org/10.1007/s00415-023-11910-z (2024) | | B cells / Plasmablasts | Cell type | CL:B cell / CL:plasmablast | Source of pathogenic AQP4-IgG (peripheral and intrathecal plasmablasts), target of anti-CD20/CD19 therapies. | (nishiyama2024antiaquaporin4immunecomplex pages 1-2, kumpfel2024updateonthe pages 1-2) | https://doi.org/10.1038/s41598-024-53661-5 (2024) | | Th17 cells | Cell type | CL:CD4-positive, alpha-beta T cell (Th17) | CD4+ Th17 lineage produces IL-17A and collaborates with IL-6-driven responses to mediate CNS inflammation in NMOSD. | (nishiyama2024antiaquaporin4immunecomplex pages 1-2, correale2025inductionofimmune pages 3-4) | https://doi.org/10.1038/s41598-024-53661-5 (2024) | | Astrocytes | Cell type | CL:astrocyte | Primary cellular target (AQP4-rich endfeet) whose antibody-mediated necrosis initiates downstream demyelination and neuronal injury. | (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, winkler2021bloodbrainbarrierresealing pages 1-2) | https://doi.org/10.1186/s41232-023-00291-5 (2023) | | Blood–brain barrier (BBB) | Anatomical / barrier structure | UBERON:blood–brain barrier | Disruption permits peripheral AQP4-IgG and complement to access astrocyte endfeet and is mediated early by PMNs and autoantibodies (e.g., anti-GRP78). | (winkler2021bloodbrainbarrierresealing pages 1-2, winkler2021bloodbrainbarrierresealing pages 11-12, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5) | https://doi.org/10.1172/jci141694 (2021) | | Optic nerve | Anatomical site | UBERON:optic nerve | A frequent clinical target producing severe optic neuritis; lesions reflect astrocyte loss, complement deposition and secondary axonal injury. | (kumpfel2024updateonthe pages 1-2, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5) | https://doi.org/10.1007/s00415-023-11910-z (2024) | | Spinal cord (LETM) | Anatomical site | UBERON:spinal cord (longitudinally extensive transverse myelitis) | Characteristic longitudinal central gray/cord lesions spanning ≥3 vertebral segments driven by astrocytopathy and complement-mediated injury. | (kumpfel2024updateonthe pages 1-2, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5) | https://doi.org/10.1007/s00415-023-11910-z (2024) | | Area postrema | Anatomical site | UBERON:area postrema | Brainstem region commonly affected in NMOSD (intractable vomiting/hiccups) due to local astrocyte-targeted inflammation. | (kumpfel2024updateonthe pages 1-2) | https://doi.org/10.1007/s00415-023-11910-z (2024) | | Hypothalamus | Anatomical site | UBERON:hypothalamus | Reported site of involvement reflecting broader astrocyte vulnerability beyond optic nerve/spinal cord. | (kumpfel2024updateonthe pages 1-2, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5) | https://doi.org/10.1007/s00415-023-11910-z (2024) | | Complement-dependent cytotoxicity (CDC) | Process | GO:complement-dependent cytotoxicity | Mechanism by which AQP4-IgG fixes classical complement and drives MAC formation and astrocyte lysis. | (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, winkler2021bloodbrainbarrierresealing pages 11-12, kumpfel2024updateonthe pages 1-2) | https://doi.org/10.1172/jci141694 (2021) | | Antibody-dependent cellular cytotoxicity (ADCC) | Process | GO:antibody-dependent cellular cytotoxicity | Fc-mediated engagement of innate effector cells (NK, neutrophils) by AQP4-IgG contributing to astrocyte injury. | (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5, nishiyama2024antiaquaporin4immunecomplex pages 1-2) | https://doi.org/10.1186/s41232-023-00291-5 (2023) | | NF-κB signaling | Process / pathway | GO:NF-kappaB signaling | Upregulated in complement/antibody-driven astrocyte stress responses and linked to IL-6 transcription and inflammation. | (nishiyama2024antiaquaporin4immunecomplex pages 1-2, kinoshita2023autoimmunemediatedastrocytopathy pages 2-5) | https://doi.org/10.1038/s41598-024-53661-5 (2024) | | Th17 polarization | Process | GO:Th17 cell differentiation | IL-6 and complement-dependent signals promote Th17 differentiation and IL-17A production that amplify CNS inflammation. | (nishiyama2024antiaquaporin4immunecomplex pages 1-2, correale2025inductionofimmune pages 3-4) | https://doi.org/10.1038/s41598-024-53661-5 (2024) | | BBB disruption | Process | GO:blood–brain barrier disruption | Early event enabling pathogenic antibody/complement entry; driven by PMN recruitment, endothelial autoantibodies and inflammatory mediators. | (winkler2021bloodbrainbarrierresealing pages 1-2, winkler2021bloodbrainbarrierresealing pages 11-12) | https://doi.org/10.1172/jci141694 (2021) | | ATP (danger signal) | Chemical / metabolite | CHEBI:ATP | Released from damaged astrocytes, ATP contributes to microglial activation and propagation of inflammatory signaling. | (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5) | https://doi.org/10.1186/s41232-023-00291-5 (2023) |

Table: Concise ontology-mapped summary of key entities, processes and anatomical sites in AQP4-IgG-positive NMOSD pathophysiology with direct evidence citations (pqac IDs) and source links/years.

Evidence items (with URLs and dates) - Kinoshita M, Okuno T. Autoimmune-mediated astrocytopathy. Inflammation and Regeneration. 2023 Jul. https://doi.org/10.1186/s41232-023-00291-5 (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5) - Nishiyama S, et al. Anti-aquaporin-4 immune complex stimulates complement-dependent Th17 cytokine release in NMOSD. Scientific Reports. 2024 Feb. https://doi.org/10.1038/s41598-024-53661-5 (nishiyama2024antiaquaporin4immunecomplex pages 1-2) - Winkler A, et al. Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration. J Clin Invest. 2021 Mar. https://doi.org/10.1172/jci141694 (winkler2021bloodbrainbarrierresealing pages 1-2, winkler2021bloodbrainbarrierresealing pages 11-12) - Kümpfel T, et al. NEMOS revised recommendations (Part II). Journal of Neurology. 2024 Sep. https://doi.org/10.1007/s00415-023-11910-z (kumpfel2024updateonthe pages 1-2) - Shimizu F, Nakamori M. Blood–brain barrier disruption in neuroimmunological disease. IJMS. 2024 Oct. https://doi.org/10.3390/ijms251910625 (shimizu2024blood–brainbarrierdisruption pages 9-10) - Yao S-Q, et al. The Role of Gut Microbiota in NMOSD. IJMS. 2024 Mar. https://doi.org/10.3390/ijms25063179 (yao2024theroleof pages 5-6) - Cho E B, et al. Differentiated complement activation: MOGAD vs AQP4-NMOSD. Frontiers in Immunology. 2024 Mar. https://doi.org/10.3389/fimmu.2024.1320094 (cho2024differentiatedpatternof pages 6-9)

Notes and limitations - While landmark historical studies (e.g., initial AQP4-IgG discoveries and PREVENT trial primary reports) predate 2023, this report prioritized 2023–2024 sources for mechanistic updates and consensus. Where exact biomarker thresholds are needed (e.g., quantitative GFAP cutoffs), readers should consult assay-specific studies; here we cite directionality and associations from recent reviews (shimizu2024blood–brainbarrierdisruption pages 9-10).

References

1. (kinoshita2023autoimmunemediatedastrocytopathy pages 2-5): Makoto Kinoshita and Tatsusada Okuno. Autoimmune-mediated astrocytopathy. Inflammation and Regeneration, Jul 2023. URL: https://doi.org/10.1186/s41232-023-00291-5, doi:10.1186/s41232-023-00291-5. This article has 4 citations.

2. (kumpfel2024updateonthe pages 1-2): T. Kümpfel, Katrin Giglhuber, O. Aktas, I. Ayzenberg, J. Bellmann-Strobl, Vivien Häußler, J. Havla, K. Hellwig, M. W. Hümmert, S. Jarius, I. Kleiter, Luisa Klotz, M. Krumbholz, Friedemann Paul, M. Ringelstein, K. Ruprecht, M. Senel, J. Stellmann, F. Bergh, C. Trebst, H. Tumani, C. Warnke, B. Wildemann, and A. Berthele. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (nmosd) – revised recommendations of the neuromyelitis optica study group (nemos). part ii: attack therapy and long-term management. Journal of Neurology, 271:141-176, Sep 2024. URL: https://doi.org/10.1007/s00415-023-11910-z, doi:10.1007/s00415-023-11910-z. This article has 198 citations and is from a domain leading peer-reviewed journal.

3. (winkler2021bloodbrainbarrierresealing pages 1-2): Anne Winkler, Claudia Wrzos, Michael Haberl, Marie-Theres Weil, Ming Gao, Wiebke Möbius, Francesca Odoardi, Dietmar R. Thal, Mayland Chang, Ghislain Opdenakker, Jeffrey L. Bennett, Stefan Nessler, and Christine Stadelmann. Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration. The Journal of clinical investigation, Mar 2021. URL: https://doi.org/10.1172/jci141694, doi:10.1172/jci141694. This article has 50 citations.

4. (winkler2021bloodbrainbarrierresealing pages 11-12): Anne Winkler, Claudia Wrzos, Michael Haberl, Marie-Theres Weil, Ming Gao, Wiebke Möbius, Francesca Odoardi, Dietmar R. Thal, Mayland Chang, Ghislain Opdenakker, Jeffrey L. Bennett, Stefan Nessler, and Christine Stadelmann. Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration. The Journal of clinical investigation, Mar 2021. URL: https://doi.org/10.1172/jci141694, doi:10.1172/jci141694. This article has 50 citations.

5. (nishiyama2024antiaquaporin4immunecomplex pages 1-2): Shuhei Nishiyama, Jin Myong Seok, Amy E. Wright, Itay Lotan, Takahisa Mikami, Natalia C. Drosu, Natasha Bobrowski-Khoury, Monique R. Anderson, Philippe A. Bilodeau, Patrick Schindler, Friedemann Paul, Masashi Aoki, Michael R. Yeaman, Michael Levy, Jacinta M. Behne, Megan K. Behne, Jeffrey L. Bennett, Terrence F. Blaschke, Tanuja Chitnis, Lawrence J. Cook, Michael Levy, Sarah M. Planchon, Pavle Repovic, Claire S. Riley, Terry J. Smith, Anthony Traboulsee, and Michael R. Yeaman. Anti-aquaporin-4 immune complex stimulates complement-dependent th17 cytokine release in neuromyelitis optica spectrum disorders. Scientific Reports, Feb 2024. URL: https://doi.org/10.1038/s41598-024-53661-5, doi:10.1038/s41598-024-53661-5. This article has 17 citations and is from a peer-reviewed journal.

6. (shimizu2024blood–brainbarrierdisruption pages 9-10): Fumitaka Shimizu and Masayuki Nakamori. Blood–brain barrier disruption in neuroimmunological disease. International Journal of Molecular Sciences, 25:10625, Oct 2024. URL: https://doi.org/10.3390/ijms251910625, doi:10.3390/ijms251910625. This article has 41 citations and is from a poor quality or predatory journal.

7. (yao2024theroleof pages 5-6): Shi-Qi Yao, Xiayin Yang, Ling-Ping Cen, and Shaoying Tan. The role of gut microbiota in neuromyelitis optica spectrum disorder. International Journal of Molecular Sciences, 25:3179, Mar 2024. URL: https://doi.org/10.3390/ijms25063179, doi:10.3390/ijms25063179. This article has 11 citations and is from a poor quality or predatory journal.

8. (cho2024differentiatedpatternof pages 6-9): Eun Bin Cho, Ju-Hong Min, Patrick Waters, Miyoung Jeon, Eun-Seon Ju, Ho Jin Kim, Su-Hyun Kim, Ha Young Shin, Sa-Yoon Kang, Young-Min Lim, Sun-Young Oh, Hye Lim Lee, Eunhee Sohn, Sang-Soo Lee, Jeeyoung Oh, Sunyoung Kim, So-Young Huh, Joong-Yang Cho, Jin Myoung Seok, Byung-Jo Kim, and Byoung Joon Kim. Differentiated pattern of complement system activation between mog-igg-associated disease and aqp4-igg-positive neuromyelitis optica spectrum disorder. Frontiers in Immunology, Mar 2024. URL: https://doi.org/10.3389/fimmu.2024.1320094, doi:10.3389/fimmu.2024.1320094. This article has 7 citations and is from a peer-reviewed journal.

9. (correale2025inductionofimmune pages 3-4): J. Correale and Edgar Carnero Contentti. Induction of immune tolerance in nmosd and mogad. Therapeutic Advances in Neurological Disorders, Jan 2025. URL: https://doi.org/10.1177/17562864251357393, doi:10.1177/17562864251357393. This article has 3 citations and is from a peer-reviewed journal.

Comprehensive Pathophysiology of Neuromyelitis Optica Spectrum Disorder

Neuromyelitis optica spectrum disorder (NMOSD) is a severe inflammatory demyelinating disease of the central nervous system characterized by relapsing attacks that cause profound disability through irreversible damage to the optic nerves, spinal cord, brainstem, and brain.[1][4][21] Unlike multiple sclerosis, which primarily targets oligodendrocytes and myelin, NMOSD is fundamentally an astrocytopathy—a disease in which astrocytes are the primary targets of autoimmune destruction.[1][3][4] The discovery of disease-specific autoantibodies against the aquaporin-4 water channel protein in 2004 revolutionized understanding of this disorder and established it as a distinct entity from multiple sclerosis based on fundamentally different immunopathological mechanisms.[3] This comprehensive analysis examines the molecular cascades, cellular interactions, and anatomical vulnerabilities that drive NMOSD pathogenesis, with particular emphasis on how autoimmune targeting of a single astrocytic protein triggers multisystem neurological failure.

The Aquaporin-4 Protein and its Pathological Role in Central Nervous System Homeostasis

Aquaporin-4 (AQP4) is the most abundant water channel protein in the central nervous system, serving critical functions in osmoregulation, fluid homeostasis, and metabolic support for neural tissue.[25][57] AQP4 is highly concentrated in astrocytic foot processes that directly contact blood vessels at the blood-brain barrier and meninges, where it mediates bidirectional water exchange and maintains extracellular space homeostasis.[3][25][57] The protein exists in two main isoforms—M1 and M23—that are regulated at the transcriptional level in a tissue and region-specific manner, with M23 predominating in most CNS regions.[3][10] These isoforms have distinct biophysical properties and subcellular localizations; while M1-AQP4 exists as isolated tetramers, M23-AQP4 preferentially assembles into large orthogonal arrays of particles (OAPs) that appear as 9-nanometer square lattices in electron microscopy studies of native astrocytic membranes.[3][10][25] The ratio of M1 to M23 expression varies significantly across different brain regions and even within individual astrocytes, with M23-enriched OAPs localizing preferentially to perivascular astroglial endfoot processes where they facilitate rapid water transport across the blood-brain barrier.[3][25]

AQP4 expression is not uniform throughout the CNS but rather concentrated in anatomically selective regions that become preferential targets for NMOSD pathology.[1][4][25] The optic nerves, spinal cord, and area postrema express particularly high levels of AQP4, with AQP4-rich astrocytes also found in the medulla, dorsal pons, hypothalamus, periaqueductal gray matter, and periventricular regions adjacent to the cerebral ventricles.[1][4][25] This selective regional concentration explains the clinical phenotype of NMOSD—the disease preferentially attacks these AQP4-rich brain regions while sparing peripheral nervous system tissues that also express AQP4 but are protected from autoimmune attack by extraneuronal regulatory mechanisms.[1][2][3] Beyond water transport, emerging evidence indicates that AQP4 plays essential roles in glymphatic fluid clearance, synaptic plasticity, memory formation, regulation of extracellular space volume, and potassium homeostasis through interactions with potassium channels like Kir4.1.[25][57] Loss of AQP4 creates bidirectional problems: reduced water entry during cytotoxic edema and impaired removal of excess fluid during vasogenic edema, both of which can exacerbate CNS injury.[3][25]

Anti-AQP4 Autoantibody Formation and Serological Classification

More than 80% of patients with NMOSD harbor circulating immunoglobulin G autoantibodies against AQP4 (termed anti-AQP4 or AQP4-IgG), making this the pathogenic hallmark and defining immunological feature of AQP4-seropositive NMOSD.[1][2][3][4] These antibodies are highly specific for NMOSD, with sensitivities and specificities ranging from 68-91% and 85-99% depending on the assay methodology used, and they are not found in healthy controls or multiple sclerosis patients.[3][4][6] The AQP4-IgG antibodies predominantly belong to the IgG1 subclass, which potently activates the classical complement pathway through binding of C1q to the constant regions (Fc domain) of clustered immunoglobulin molecules.[10][29][39] Importantly, many AQP4-IgGs preferentially bind to orthogonal arrays of particles rather than monomeric AQP4, suggesting that conformational epitopes composed of multiple interactions from neighboring tetramers within OAPs are critical for antibody recognition.[10] This preferential binding to OAPs has significant pathogenic implications, as multivalent binding of AQP4-IgG to clustered AQP4 molecules facilitates assembly of hexameric antibody complexes that efficiently activate complement by bringing multiple C1q molecules into proximity.[10]

The etiology of anti-AQP4 autoantibody formation remains incompletely understood, though multiple mechanisms contributing to loss of immune tolerance have been proposed.[4][5][14] Genetic predisposition plays a clear role, with specific HLA alleles—particularly HLA-DRB108:02, HLA-DRB116:02, and related class II MHC molecules—identified as risk factors for NMOSD.[4][5][18] These HLA variants likely present AQP4-derived peptides to autoreactive T cells in a manner that breaks peripheral tolerance.[4] Abnormalities in thymic tolerance have also been implicated, as normally thymic B cells express AQP4 in a CD40-dependent manner, which promotes negative selection of AQP4-specific T cells and prevents their survival in the periphery.[14][39] In NMOSD patients, dysregulation of this protective mechanism allows autoreactive T cells to escape negative selection and persist in circulation.[14] Environmental triggers contribute significantly to autoimmune activation; approximately 20-30% of NMOSD attacks are preceded by infections or vaccinations, suggesting that molecular mimicry or bystander activation may initiate or exacerbate disease.[4][15] Specific microbial agents have been implicated, including Epstein-Barr virus, Mycobacterium paratuberculosis, and Helicobacter pylori, which are detected with increased frequency in NMOSD patient sera.[15] Vitamin D deficiency, smoking, and dietary factors (particularly high carbohydrate and low dairy intake) have emerged as modifiable environmental risk factors that may facilitate disease development.[15]

The presence of AQP4-IgG is a critical biomarker with direct pathogenic significance rather than a mere epiphenomenon of disease.[3][6] Serum AQP4-IgG titers generally increase before clinical relapses and decline during remission, suggesting a relationship between antibody levels and disease activity.[1][2][12] Passive transfer experiments in animal models definitively prove pathogenicity: intracerebral injection of patient-derived AQP4-IgG together with human complement reproduces the characteristic histological lesions of NMOSD, including loss of AQP4 immunoreactivity, astrocyte death marked by loss of glial fibrillary acidic protein (GFAP), perivascular immunoglobulin and complement deposition, and infiltration of inflammatory cells.[3][7][15] Importantly, these lesions do not develop when complement is inactivated or when AQP4-IgG is introduced into AQP4 knockout mice, conclusively demonstrating that both the antibody and complement cascade are required for disease pathogenesis.[7]

The mechanistic relationship between AQP4-IgG and complement-mediated astrocyte destruction appears to occur through multiple pathways that may operate simultaneously. In the classical pathway, circulating AQP4-IgG enters the CNS at sites where the blood-brain barrier is compromised or naturally permeable, such as the area postrema and circumventricular organs.[1][2][16] Once within the CNS parenchyma, AQP4-IgG binds to its target antigen on astrocyte foot processes, establishing the initial point of contact between the autoimmune system and the CNS. This binding operates through both monovalent and multivalent mechanisms; when individual AQP4-IgG molecules bind to single AQP4 tetramers, they engage in extended interactions that expose epitopes on adjacent tetramers within OAP structures, allowing a single antibody to sequentially bind multiple AQP4 molecules in a conformationally dependent manner.[10] However, the highest efficiency of complement activation occurs when multiple AQP4-IgG molecules bind in close spatial proximity to create a multivalent platform for C1q binding, with geometric arrangements of antibodies—particularly hexameric assemblies—proving optimal for complement engagement.[10] The complement cascade activated by AQP4-IgG follows the classical pathway, progressing from C1q engagement through the sequential activation of C1r, C1s, C4, and C2, continuing through amplification steps involving C3 and C5, and culminating in formation of the membrane attack complex (MAC or C5b-9).[7][29][39] The MAC creates pore-like structures in the plasma membrane of targeted astrocytes, allowing uncontrolled ionic and osmotic flux that ultimately results in cell lysis and death.[7][29][39]

Notably, approximately 20-25% of patients meeting clinical criteria for NMOSD are seronegative for AQP4-IgG and MOG-IgG antibodies, termed double-negative NMOSD.[9][56][59] These patients present a pathophysiological challenge, as the primary autoantigen remains unidentified, yet they experience clinical and pathological features qualitatively similar to AQP4-IgG-positive disease. Recent evidence suggests that double-negative NMOSD may be pathophysiologically heterogeneous, potentially encompassing multiple distinct diseases with different underlying mechanisms.[59] Some double-negative cases appear to have profound primary demyelination with less prominent astrocytopathy, as indicated by cerebrospinal fluid measurements of glial fibrillary acidic protein that are lower than in AQP4-IgG-positive disease, suggesting a different underlying pathophysiology.[9] Other evidence indicates that certain double-negative cases involve antibodies against additional CNS autoantigens not routinely tested, including glial fibrillary acidic protein, flotillin, connexin-43, and aquaporin-1.[2][59] Importantly, CSF neurofilament light chain levels are paradoxically elevated in double-negative NMOSD, sometimes exceeding levels seen in AQP4-IgG-positive disease, suggesting that neuronal-axonal damage in double-negative cases may be as severe or more severe than in antibody-positive disease despite the absence of identified autoantibodies.[59]

The Complement-Dependent Cytotoxicity Cascade: Primary Effector Mechanism of Astrocyte Destruction

The complement-dependent cytotoxicity (CDC) pathway represents the principal mechanism by which AQP4-IgG antibodies initiate astrocyte destruction, particularly in AQP4-IgG-seropositive NMOSD.[3][7][14][29][39] Once AQP4-IgG binds to its target antigen on the astrocyte membrane, the constant region of the IgG molecule presents conformational epitopes recognized by C1q, the recognition component of the classical complement pathway.[7][29][39] C1q binding initiates a conformational cascade in which the serine proteases C1r and C1s become activated and sequentially cleave the complement components C4 and C2, generating the C3 convertase (C4b2a), which initiates the common pathway of complement activation.[7][29][39] The C3 convertase cleaves C3 into C3a and C3b fragments; C3b covalently binds to the cell surface in the vicinity of the antibody-antigen complexes, while C3a diffuses away as a potent anaphylatoxin.[7][29][39] Surface-bound C3b recruits additional factors to form the C5 convertase, which cleaves C5 into C5a and C5b fragments; C5a is released as a powerful neutrophil chemoattractant, while C5b remains bound to the membrane and initiates the terminal complement cascade.[7][29][39] The terminal cascade involves sequential binding of complement components C6, C7, C8, and C9, culminating in the formation of the membrane attack complex (MAC or C5b-9), a pore-like structure approximately 10 nanometers in diameter that permits uncontrolled movement of ions and water across the plasma membrane.[7][29][39]

The complement cascade initiated by AQP4-IgG produces a cascade of cytotoxic events within targeted astrocytes.[3][7][29][39] Historically, cell death was attributed primarily to direct lytic action of the membrane attack complex, which creates osmotic stress by allowing massive influx of sodium ions and water, leading to cell swelling and eventual rupture of the plasma membrane.[3][7][39] However, more recent mechanistic studies have revealed that complement-dependent astrocyte death in NMOSD involves additional pathways beyond direct MAC lysis, including complement-dependent cellular cytotoxicity (CDCC) and antibody-dependent cellular cytotoxicity (ADCC) mediated by infiltrating immune cells.[3][14][39][42] In the CDC pathway, production of C3a and C5a anaphylatoxins during complement activation triggers recruitment of neutrophils, eosinophils, macrophages, and NK cells to the sites of complement-mediated astrocyte damage.[7][14][29][39] These infiltrating cells recognize Fc regions of surface-bound IgG through their Fcγ receptors and become activated, leading to degranulation and release of cytotoxic proteins including neutrophil elastase, eosinophil cationic protein, and major basic protein.[7][14][29][39][42] The magnitude of complement activation in NMOSD is particularly pronounced because the orthogonal arrays of particles that are the preferred target of AQP4-IgG present a highly ordered, multivalent surface arrangement that maximizes C1q binding and amplification.[3][10][29]

The consequence of complement-driven astrocyte death is catastrophic loss of CNS cellular architecture and function.[3][7][14][29][39] Extensive perivascular deposition of activated complement components C9neo (the terminal fragment of the membrane attack complex) and immunoglobulins (particularly IgM) occurs in active NMOSD lesions, with pronounced involvement of both gray and white matter.[3][7][29][39][49] The astrocyte loss creates a profound local inflammatory vacuum; astrocytes normally provide critical homeostatic functions including glutamate uptake and recycling, regulation of extracellular ion concentrations (particularly potassium), provision of lactate as a fuel for neurons, and maintenance of the blood-brain barrier through their contact with endothelial cells.[1][3][7][29] The loss of these supportive functions creates secondary damage to nearby oligodendrocytes and neurons even though these cells are not directly targeted by AQP4-IgG, a phenomenon termed bystander injury.[7][14] Studies using cultured astrocyte-neuron cocultures have demonstrated that exposure to AQP4-IgG and complement results in death of neurons localized adjacent to astrocytes; notably, C5b-9 membrane attack complexes are detected on neuronal membranes despite neurons not being direct antibody targets, indicating that complement activation initiated on astrocytes propagates to nearby cells through diffusion of soluble activated complement components.[7] Following astrocyte death and loss of myelin support, oligodendrocytes undergo secondary degeneration, leading to demyelination of previously myelinated axons.[3][7][14]

Polymorphonuclear Leukocytes as Central Mediators of Blood-Brain Barrier Disruption

While complement activation and astrocyte destruction represent the primary immunopathological cascade in NMOSD, the subsequent recruitment and activation of polymorphonuclear leukocytes (PMNs, principally neutrophils) drives critical expansion of the lesion and causes blood-brain barrier disruption that amplifies autoimmune injury.[17][26][37][49] Studies in experimental NMOSD models demonstrate that PMNs are already abundant in developing lesions by six hours after AQP4-IgG and complement introduction, reaching peak density between 12 and 24 hours, with PMN numbers at lesion sites exceeding those of macrophages or T lymphocytes at these early timepoints.[17][26] Mechanistically, complement-derived anaphylatoxins C3a and C5a function as potent chemoattractants, with C5a in particular inducing expression of adhesion molecules on brain endothelial cells and promoting trans-endothelial migration of circulating neutrophils into the CNS parenchyma.[17][26][37] Once infiltrated into lesions, PMNs undergo activation and degranulation, releasing proteolytic enzymes including neutrophil elastase and matrix metalloproteinase-9 that degrade components of the blood-brain barrier's tight junctions, particularly the transmembrane proteins claudins and occludin that maintain the sealed nature of the barrier.[17][26][37] The disruption of blood-brain barrier integrity is transient and self-limiting, with BBB function reestablishing before astrocytes repopulate the lesion site, suggesting that PMN-mediated barrier disruption is a distinct phase of pathology that precedes astrocyte regeneration.[17][26]

The PMN-mediated phase of NMOSD pathogenesis proves therapeutically important because selective blockade of PMN recruitment or inhibition of their proteolytic functions significantly reduces lesion size and astrocyte loss in experimental models.[17][26] Depletion of circulating PMNs or blockade of the C5a receptor (C5aR) that mediates neutrophil recruitment substantially decreases astrocyte loss and reduces the area of demyelination compared to control-treated animals.[17][26] Similarly, inhibition of matrix metalloproteinase-9, a key PMN protease involved in blood-brain barrier degradation, significantly reduces astrocyte loss, though the effect on PMN infiltration itself is modest, suggesting that the proteolytic functions of infiltrating PMNs may be more critical than their numbers for driving lesion expansion.[17][26] These findings have important implications for understanding why complement inhibition has proven therapeutically effective in NMOSD clinical trials—complement inhibitors prevent both the direct cytotoxic effects of MAC formation on astrocytes and the secondary amplification of injury through PMN recruitment and activation.[17][26][43]

Blood-Brain Barrier Dysfunction and Pathogenic Antibody Entry into the CNS

A critical unsolved question in NMOSD pathogenesis concerns the mechanisms by which serum AQP4-IgG antibodies initially breach the blood-brain barrier to access their target antigen on astrocytes, given that the blood-brain barrier normally restricts passage of large protein molecules like immunoglobulins.[1][2][16][26][37] The available evidence suggests multiple, possibly sequential mechanisms of BBB compromise in NMOSD. First, the area postrema—a circumventricular organ at the junction of the medulla and fourth ventricle—appears to serve as an initial portal of entry for circulating AQP4-IgG.[13][16][52] Unlike most brain regions, the area postrema has naturally permeable endothelial cells that lack tight junctions and are exposed to circulating blood factors, facilitating direct contact between serum-derived antibodies and the abundant AQP4 expressed on local astrocytes.[13][16] The anatomical and vascular characteristics of the area postrema create conditions favoring AQP4-IgG accumulation: it is one of the most highly vascularized brain regions with an exceptionally high surface area-to-permeability ratio, and slowing of blood flow by specialized pericapillary "pools" of interstitial fluid increases local exposure of neural cells to bloodborne constituents.[13] Pathological and MRI studies consistently demonstrate that the area postrema is selectively targeted in most NMOSD cases, suggesting it may serve as the preferential entry site for initiating CNS autoimmunity.[13][16][52]

Secondary mechanisms of blood-brain barrier disruption occur through IL-6-dependent and Th17 cell-dependent pathways that compromise tight junction proteins and upregulate endothelial cell adhesion molecules.[16][27][37][40] IL-6 is a multifunctional proinflammatory cytokine that is markedly elevated in both serum and cerebrospinal fluid of NMOSD patients and correlates with disease activity and severity.[27][30] IL-6 signaling through its receptor complex activates the JAK-STAT3 pathway in endothelial cells, leading to downregulation of tight junction proteins including claudins and occludin, thereby increasing paracellular permeability and allowing infiltration of circulating factors including antibodies and immune cells.[27][37] IL-6 additionally promotes differentiation of naive T cells into pathogenic Th17 cells through activation of STAT3, and Th17 cells produce IL-17 which itself disrupts endothelial tight junctions and promotes transendothelial migration of neutrophils and eosinophils.[27][37][40] Polymorphic variations in genes regulating IL-6 signaling have been associated with NMOSD susceptibility, and IL-6 pathway blockade has proven effective in reducing NMOSD relapse rates in clinical trials, underscoring the pathogenic importance of this cytokine.[27][43]

A particularly striking mechanism of blood-brain barrier disruption involves the leptomeningeal membrane, the tissue layer surrounding the brain and spinal cord.[16] Recent neuroimaging studies have identified leptomeningeal enhancement (LME) on contrast-enhanced MRI in NMOSD patients during acute relapses, representing disruption of the blood-CSF barrier distinct from the parenchymal blood-brain barrier.[16] Leptomeningeal enhancement is frequently observed in association with initial area postrema attacks or signs of systemic infection, followed by progressive intraparenchymal enhancement, suggesting a cascade in which primary blood-CSF barrier disruption at the leptomeningeal level facilitates entry of AQP4-IgG into the subarachnoid space, from which the antibody can access the brain parenchyma through pial vessels and dorsal root entry zones.[16] The potential contribution of the leptomeningeal barrier to NMOSD pathogenesis represents an underappreciated dimension of the disease that may explain why some NMOSD attacks spread dynamically from initially involved regions to more extensive areas of the CNS over days to weeks.[16]

Molecular and Cellular Mechanisms of Axonal Injury in NMOSD

Although the primary autoimmune target in AQP4-IgG-positive NMOSD is the astrocyte, the clinical disability experienced by patients results predominantly from irreversible axonal damage and neuronal loss rather than from demyelination per se.[3][7][14][31][34][45] This distinction carries critical importance for understanding disease pathophysiology and predicting outcomes. Pathological studies reveal that axonal damage often precedes demyelination in NMOSD, suggesting that loss of astrocyte-derived support directly harms axons rather than serving as a secondary consequence of myelin loss.[3][21][55] The mechanisms of NMOSD-related axonal injury differ fundamentally from the demyelinating pathology of multiple sclerosis; whereas MS involves focal axonal degeneration or Wallerian-like degeneration programs, recent in vivo imaging studies of NMOSD lesion models demonstrate that axonal injury involves a distinct mechanism involving osmotic stress and ionic overload coupled with disruption of axonal cytoskeletal architecture.[45] Specifically, high-resolution two-photon microscopy of mouse spinal cord reveals early beading and fragmentation of axons in AQP4-IgG-induced lesions, with subcellular analysis showing local loss of microtubules—the rigid structural elements that maintain axonal caliber and cytoplasmic organization.[45] This axonal microtubule disruption can be prevented by treatment with epothilone, a microtubule-stabilizing agent, providing direct evidence that microtubule destabilization represents a tractable therapeutic target in NMOSD.[45]

The loss of astrocytic AQP4 directly contributes to osmotic derangements that stress axons.[3][7][29] Under normal conditions, AQP4 water channels on astrocyte foot processes facilitate rapid water movement to buffer osmotic gradients generated by neuronal activity; loss of this osmotic buffering capacity during NMOSD attacks creates local areas of osmotic imbalance.[3][7][25] Additionally, astrocytes normally maintain extracellular potassium homeostasis through uptake of potassium released during neuronal firing via Na+/K+-ATPase pumps and Kir4.1 potassium channels; AQP4 interacts functionally with Kir4.1 and is required for optimal potassium uptake and buffering.[25][57] Following astrocyte death, accumulation of extracellular potassium reaches levels that depolarize axonal membranes, compromising the resting membrane potential and impairing action potential propagation.[3][7][29] Loss of astrocytic glutamate uptake transporters (particularly EAAT2/GLT-1) leads to accumulation of extracellular glutamate that can activate ionotropic glutamate receptors on axons and neurons, causing additional calcium influx and excitotoxic damage.[3][7][29] The combined effects of osmotic stress, ionic imbalance, and excitotoxicity on axons lacking astrocytic support create multiple pathways toward structural failure and degeneration.

Complement-mediated bystander injury to oligodendrocytes and neurons contributes additional pathology beyond direct astrocyte targeting.[7][14][42] While oligodendrocytes and neurons are not primary targets of AQP4-IgG, complement activation initiated on nearby astrocytes generates soluble activated complement components including C5b fragments and MAC precursors that diffuse into surrounding tissue and deposit on neighboring cells.[7][14][42] Remarkably, C5b-9 membrane attack complexes are consistently detected on oligodendrocyte and neuronal membranes in active NMOSD lesions despite these cells not being bound by pathogenic antibodies, indicating passive deposition through complement diffusion.[7][14][42] This bystander mechanism explains the extensive oligodendrocyte loss and demyelination that occurs in NMOSD despite antibodies targeting astrocytes rather than myelin-producing cells.[7][14] The phenomenon of complement-mediated bystander injury likely extends beyond oligodendrocytes to nearby neurons; indeed, cultured neuron-astrocyte cocultures exposed to AQP4-IgG and complement show neuronal death with C5b-9 deposition on neuronal membranes despite neurons not being antibody targets.[7] This suggests that the extensive axonal and neuronal loss characteristic of NMOSD results both from loss of astrocytic support functions and from direct complement-mediated injury propagated to neighboring cells through diffusion of activated complement components.[7][14][42]

Role of Microglia and Innate Immune Activation in NMOSD Pathogenesis

While B cells producing AQP4-IgG and CD4+ T cells providing help to B cells represent the adaptive immune components of NMOSD pathogenesis, mounting evidence indicates that microglia and macrophages—resident and infiltrating innate immune cells—play critical regulatory roles in amplifying inflammation and driving tissue destruction.[20][23][42] Microglia are professional phagocytes derived from yolk sac progenitors that pervade the CNS and serve as the resident innate immune population, capable of rapid activation in response to danger signals.[20][42] Neuropathological analysis of human NMOSD lesions consistently demonstrates prominent infiltration and activation of macrophages and microglia, with distribution patterns corresponding to regions of high AQP4 expression and complement activation.[20][42] AQP4-IgG can directly activate microglia through multiple mechanisms; recent studies show that AQP4-IgG-induced activation of astrocytes leads to production of IL-6 and other cytokines that activate microglia, creating a complex cellular crosstalk between astrocytes and microglia that amplifies the inflammatory response.[20][42] Additionally, complement-derived anaphylatoxins C3a and C5a generated during the complement cascade directly activate microglial complement receptors, triggering morphological transformation from resting to amoeboid activated states and inducing production of proinflammatory cytokines including TNF-α, IL-1β, and IL-6.[20][42]

Microglia in NMOSD lesions adopt a predominantly pro-inflammatory M1 phenotype characterized by production of high levels of IL-1β, IL-6, TNF-α, and the chemokine CXCL10 that further recruits immune cells to lesion sites.[20][42] Type I interferon signaling additionally activates microglia in NMOSD; chronic interferon-β production in the CNS drives microglial activation as indicated by expansion of pro-inflammatory CD11c+ microglial subsets, and notably, interferon-β treatment—a standard therapy for multiple sclerosis—exacerbates NMOSD severity in both patients and experimental models, highlighting the distinct immunopathology of these diseases.[20][42] The products released by activated microglia perpetuate the inflammatory cascade through multiple mechanisms. IL-1β produced by microglia further increases blood-brain barrier permeability, allowing additional recruitment of peripheral immune cells.[20] TNF-α and IL-6 from microglia promote differentiation of infiltrating T cells toward pathogenic Th17 phenotypes that produce IL-17, perpetuating a vicious cycle of T cell activation and BBB disruption.[20][42] Complement products generated during the CDC cascade (particularly C5a) activate microglia through complement receptors, while C5a additionally recruits neutrophils that degranulate and release additional complement fragments, establishing a positive feedback loop in which initial complement activation recruits innate immune cells that generate additional complement fragments, amplifying the cascade.[20][42]

B Cell Biology and Pathogenic Autoantibody Production in NMOSD

The pathogenic role of AQP4-IgG antibodies in NMOSD makes B cells and plasma cells central to disease pathogenesis.[14][39] B cells are not merely passive producers of pathogenic antibodies but active participants in disease through multiple mechanisms including antigen presentation, cytokine production, and follicular helper T cell activation.[14][17][39][42] Mechanistically, NMOSD is thought to initiate when self-reactive B cells that have escaped negative selection in bone marrow and thymus become activated in secondary lymphoid organs through T cell help, proliferate, differentiate into plasma cells and memory B cells, and secrete AQP4-specific IgG.[14][39] The normally protective negative selection mechanisms that eliminate autoreactive B cells early in development appear compromised in NMOSD. Thymic B cells normally express AQP4 in a CD40-dependent manner, which promotes negative selection of AQP4-specific T cells and prevents their survival, thereby indirectly protecting against AQP4-specific B cell activation in the periphery.[14][39] In NMOSD patients, dysfunction or reduced efficiency of this thymic selection process allows AQP4-specific T cells to persist and provide help to B cells in secondary lymphoid tissues.[14][39] Additionally, early B cell tolerance mechanisms that eliminate newly formed autoreactive B cells in the bone marrow through negative selection appear defective, as evidenced by the presence of expanded populations of AQP4-specific B cells in NMOSD patient blood even during remission.[14][39]

Within the CNS, evidence of active B cell maturation and activation indicates that AQP4-specific B cells recognize antigen within the brain itself.[14][17] B cells recovered from cerebrospinal fluid of NMOSD patients show patterns of somatic hypermutation indicative of antigen-driven selection within the CNS, proving that B cells have encountered their cognate antigen in brain tissue rather than merely representing peripheral cells that have migrated into the CNS.[14][17] Furthermore, cerebrospinal fluid from NMOSD patients contains markedly elevated levels of B cell-activating factors including BAFF, APRIL, and CXCL13, along with IL-6, all of which promote B cell survival, proliferation, and differentiation into antibody-secreting cells.[14][17][42] These CSF findings suggest that a specialized microenvironment within the CNS actively supports survival and perpetuation of pathogenic AQP4-specific B cells, potentially explaining why NMOSD relapses can occur even in patients on systemic immunosuppression that reduces peripheral B cell populations.[14][17] Interestingly, eosinophils infiltrating lesions may facilitate this CNS B cell survival; eosinophils produce APRIL, IL-6, and IL-5 that promote plasma cell survival and enhance antibody secretion.[42][49]

The role of regulatory B cells—a suppressive B cell subset that produces anti-inflammatory cytokines IL-10, IL-35, and TGF-β—appears impaired in NMOSD.[14][39][42] While healthy individuals maintain populations of regulatory B cells that suppress pathogenic T cell responses, NMOSD patients show reduced numbers and function of this suppressive subset, removing an important brake on autoimmunity.[14][39] B cells in NMOSD also participate in antibody-independent pathogenic mechanisms through their role as antigen-presenting cells that present AQP4-derived peptides to CD4+ T cells, promoting differentiation toward pathogenic Th17 phenotypes.[14][17][39] This antigen-presentation function creates a positive feedback loop in which B cells present antigen to T cells, which provide IL-21 and CD40 ligand help back to B cells, promoting further B cell differentiation into plasma cells and memory B cells.[14][39] The importance of B cells for NMOSD pathogenesis is underscored by the clinical efficacy of B cell-depleting therapies including rituximab (anti-CD20), which reduces NMOSD relapse rates by 88-97%, and inebilizumab (anti-CD19), which provides sustained B cell depletion and reduces relapse risk by 77%.[43][44]

T Cell Dysregulation and IL-6 Production in NMOSD

Although adaptive humoral immunity through AQP4-IgG antibodies is the primary effector arm in NMOSD, CD4+ T cells play essential supporting roles in B cell activation and in promoting blood-brain barrier dysfunction through IL-6 and IL-17 production.[14][17][27][30][39] The IgG1 subclass predominance of AQP4-IgG indicates that class-switched antibodies are present, which requires T cell help; CD4+ T cells provide this help through secretion of IL-21 and expression of CD40 ligand (CD40L) that engage CD40 on B cells and provide costimulatory signals for B cell differentiation into plasma cells.[14][39] T cell dysregulation in NMOSD appears to involve a shift in the balance between pathogenic Th17 cells (which produce IL-17) and suppressive regulatory T cells (Tregs, which produce IL-10 and TGF-β), with increased frequencies of Th17 cells and reduced Treg function contributing to uncontrolled autoimmunity.[14][27][30][38][39] IL-6 produced by activated B cells, macrophages, and microglia drives this Th17 skewing by promoting STAT3 activation in CD4+ T cells and suppressing differentiation of Tregs, creating a vicious cycle in which IL-6 production amplifies Th17 responses while simultaneously reducing the anti-inflammatory Treg population.[27][30][38][39]

IL-17 produced by Th17 cells contributes to NMOSD pathogenesis through multiple mechanisms including disruption of the blood-brain barrier and recruitment of additional inflammatory cells.[27][30][40] IL-17 acts on endothelial cells to increase expression of cell adhesion molecules and reduce expression of tight junction proteins, thereby increasing BBB permeability and promoting trans-endothelial migration of neutrophils and other inflammatory cells.[27][30][40] Elevated CSF and serum IL-17 levels correlate with NMOSD disease activity, and Th17 cell numbers in the CNS increase during relapses.[27][30] Animal models of NMOSD demonstrate that blocking IL-17 signaling reduces disease severity, indicating that Th17 cells represent a tractable therapeutic target.[27] The dysregulation of IL-6/Th17 balance in NMOSD likely involves both genetic and environmental factors; genome-wide association studies have identified polymorphisms in genes regulating IL-6 signaling and T cell differentiation as NMOSD susceptibility loci, while environmental triggers including infections may activate autoreactive Th17 cells through molecular mimicry or bystander activation.[5][15][27]

Notably, CD8+ T cells also appear to contribute to NMOSD pathogenesis. Recent mechanistic studies indicate that MHC class I-related biological processes and CD8+ T cells may be involved in NMOSD coexisting with other autoimmune diseases including systemic lupus erythematosus and Sjögren syndrome.[5][14] CD8+ T cells can directly kill astrocytes through T cell receptor recognition of AQP4-derived peptides presented on MHC class I molecules, potentially representing an additional mechanism of astrocyte destruction beyond complement-mediated pathways.[14] The relative contribution of CD8+ versus CD4+ T cells to overall NMOSD pathogenesis remains to be fully elucidated, but emerging evidence suggests that both pathogenic CD4+ and CD8+ T cell populations contribute to disease.[14]

Eosinophils as Amplifiers of NMOSD Inflammation

Eosinophils, which are relatively rare in the healthy CNS, infiltrate NMOSD lesions in striking abundance, particularly in spinal cord lesions where perivascular and meningeal eosinophil infiltration represents a characteristic histological feature.[14][29][42][49] The preferential recruitment of eosinophils to NMOSD lesions rather than MS lesions suggests a distinct inflammatory microenvironment in NMOSD that specifically supports eosinophil recruitment and survival. The chemokine eotaxin (CCL11) and its receptor CCR3 are highly expressed in NMOSD lesions, with cerebrospinal fluid from NMOSD patients containing elevated levels of eotaxin-2, eotaxin-3, and eosinophil cationic protein (ECP) compared to MS patients and controls.[14][42][49] Once activated, eosinophils release multiple cytotoxic proteins including ECP, eosinophil-derived neurotoxin (EDN), eosinophil peroxidase (EPX), and major basic protein (MBP).[14][42][49] These cationic proteins are capable of creating cell membrane damage through mechanisms distinct from complement, and they contribute to neural tissue damage through antibody-dependent cellular cytotoxicity.[14][42][49] Eosinophils additionally serve as an important source of IL-5 and other cytokines that promote B cell survival and enhance AQP4-IgG production.[42][49]

Anti-MOG Antibodies and MOGAD: Distinct Pathophysiology Within the NMOSD Spectrum

While AQP4-IgG-positive NMOSD represents the predominant and most studied form of NMOSD, myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) constitutes a second major antibody-mediated demyelinating disease that presents with overlapping clinical features but distinct underlying pathophysiology.[8][11][24] MOG is an integral membrane glycoprotein expressed on the surface of oligodendrocytes and on the outermost surface of myelin sheaths, making it a surface-accessible target unlike AQP4 which is primarily located on astrocyte endfeet.[8][11] MOG-IgG antibodies comprise a smaller proportion of the NMOSD spectrum (approximately 10-40% of AQP4-seronegative patients), yet they are highly specific for MOGAD and absent in MS and healthy controls.[2][8][11] The pathophysiology of MOGAD differs fundamentally from AQP4-NMOSD: MOGAD primarily affects oligodendrocytes and myelin with relative sparing of astrocytes, produces CD4-dominated rather than CD8-dominated T cell responses, and displays predominantly monophasic clinical courses in 40-50% of cases compared to relapsing courses in 90% of AQP4-NMOSD.[8]

The mechanism of MOG antibody pathogenicity involves multiple complementary pathways including opsonization of MOG, complement activation, and antibody-dependent cellular cytotoxicity, though the relative contributions of these pathways may differ from AQP4-NMOSD.[8] MOG-IgG can opsonize MOG on oligodendrocyte surfaces, marking these cells for destruction by complement and cellular cytotoxicity mechanisms, though the efficiency of complement activation by MOG-IgG is lower than for AQP4-IgG.[8] This lower complement activation efficiency may be explained by the bivalent binding pattern of MOG-IgG (requiring both Fab subunits to engage MOG), which produces less efficient C1q activation compared to the monovalent binding pattern of many AQP4-IgGs, suggesting that anti-complement therapy may prove less effective in MOGAD than in AQP4-NMOSD.[8] MOG-IgG also causes direct intracellular signaling effects in oligodendrocytes; binding of MOG-IgG to MOG activates MAPK and AKT survival pathways and increases intracellular calcium, while cross-linking of MOG-IgG molecules leads to activation of stress-related pathways and impaired cytoskeletal integrity.[8] ADCC represents an important pathogenic mechanism in MOGAD, with NK cells and macrophages activated through Fc receptor binding causing cytotoxic destruction of MOG-expressing oligodendrocytes.[8]

The clinical course of MOGAD frequently differs from AQP4-NMOSD in ways reflecting the distinct target antigen and underlying pathophysiology. MOGAD optic neuritis presentations often feature bilateral rather than unilateral involvement, prominent optic disc edema (in up to 80% of cases compared to only one-third of MS-ON), and superior steroid responsiveness.[11] The presence of optic disc edema in MOGAD ON stands in sharp contrast to typical MS-ON which usually presents with retrobulbar (behind the optic nerve head) inflammation and thus little optic disc swelling; this difference may reflect differential targeting of Müller cells in the retina which express MOG but not AQP4.[11] Importantly, the monophasic course observed in many MOGAD patients contrasts with the relapsing course of AQP4-NMOSD; approximately 40-50% of MOGAD patients experience a single demyelinating event without subsequent relapses, though the remaining 50-60% experience relapsing disease.[8][11] When MOGAD does relapse, increasing age at first attack is associated with higher risk of permanent visual loss, whereas in AQP4-NMOSD both first and subsequent attacks frequently cause irreversible disability regardless of age.[8][11]

Environmental Risk Factors and Genetic Predisposition in NMOSD Etiology

The discovery that NMOSD results from autoimmune targeting of a specific CNS protein (AQP4) has not fully explained why certain individuals develop this autoimmunity while others exposed to identical genetic backgrounds do not, pointing to critical roles for environmental and epigenetic factors in disease pathogenesis.[5][15][18] Genome-wide association studies have identified multiple genetic loci that increase NMOSD risk, with HLA class II molecules being the most consistently implicated genetic factors, followed by polymorphisms in genes regulating IL-6 signaling, complement activation, and T cell differentiation.[5][15][18][19] Specific HLA alleles including HLA-DRB108:02, HLA-DRB116:02, and related molecules confer increased NMOSD susceptibility, while HLA-DRB1*09:01 is associated with lower risk, suggesting that presentation of AQP4-derived peptides to T cells by these class II MHC molecules determines susceptibility.[5][18][19] The genetic association profile of NMOSD shows greater similarity to systemic lupus erythematosus than to MS, despite NMOSD being a CNS-specific disease, suggesting shared genetic architecture underlying autoimmune predisposition across these systemic and organ-specific diseases.[4][5]

Vitamin D deficiency emerges as a consistent modifiable environmental risk factor associated with NMOSD development.[15] A systematic scoping review identified vitamin D deficiency in 92.1% of NMOSD patients compared to 66.2% of controls, with particularly striking deficiency rates (vitamin D < 50 nmol/L) in NMOSD populations.[15] Mechanistically, vitamin D deficiency may impair immune tolerance by reducing Treg differentiation and expansion while promoting Th17 cell development, creating a permissive environment for autoimmunity.[15] The latitude effect observed in MS (with higher prevalence at higher latitudes with less sun exposure) does not appear as prominent in NMOSD, yet vitamin D deficiency remains a significant modifiable factor.[15] Smoking represents another environmental risk factor, with NMOSD patients more likely to be current or former smokers than healthy controls, suggesting that tobacco-derived toxins or immune-modulating effects of smoking may contribute to disease development.[15]

Infectious triggers appear important in NMOSD pathogenesis, with approximately 20-30% of NMOSD attacks occurring within one month of infection or vaccination.[4][15] Specific infectious agents are more frequently detected in NMOSD patient sera, including Epstein-Barr virus (detected with higher antibody titers than in controls), Mycobacterium paratuberculosis, and Helicobacter pylori, suggesting molecular mimicry between epitopes on these pathogens and AQP4.[4][15] The mechanism may involve T cell and B cell responses initially directed against pathogen-derived epitopes that cross-react with AQP4 sequences, a process known as molecular mimicry, or alternatively bystander activation in which local inflammation at the infection site activates nearby autoreactive lymphocytes that have nothing to do with the pathogenic trigger.[4][15] Pregnancy-related immunosuppression influences NMOSD disease activity; approximately 20-47% of women develop their first NMOSD symptoms during pregnancy or within one year postpartum.[1] The mechanisms involve pregnancy-induced changes in immune regulation including elevated estrogen levels that decrease apoptosis of self-reactive B cells, increased Th17 cells, and reduced regulatory T cell function.[1]

Dietary factors have been associated with NMOSD risk; studies show that high carbohydrate consumption combined with low dairy product intake correlates with increased NMOSD occurrence, possibly through effects on the microbiota composition that influences immune homeostasis.[15] The marked geographic variation in NMOSD prevalence, with substantially higher rates in Asian and African populations compared to European Caucasians, may reflect combinations of genetic predisposition, environmental exposures, and infectious triggers that vary by region.[1][4][5]

Clinical Manifestations and Their Anatomical Basis

The clinical phenotype of NMOSD results directly from the selective vulnerability of specific CNS regions to AQP4-IgG-mediated autoimmunity, particularly areas of highest AQP4 expression.[1][4][21][52][55] Optic neuritis represents a core clinical feature affecting the majority of NMOSD patients, manifesting as acute vision loss accompanied by eye pain and featuring distinctive imaging findings and visual outcomes that differ from MS-related optic neuritis.[1][4][21][32][52][55] NMOSD-related optic neuritis (ON) typically causes severe visual acuity loss, with over 75% of patients experiencing acuity of 20/200 or worse at nadir compared to approximately 36% in MS-ON patients, translating into clinically meaningful differences in long-term visual disability.[1][32] The anatomical distribution of NMOSD optic nerve lesions differs from MS; NMOSD preferentially affects the posterior optic nerve and optic chiasm rather than the anterior optic nerve, with bilateral simultaneous or rapidly sequential involvement occurring in a significant proportion of NMOSD patients versus isolated unilateral disease being typical in MS.[1][21][32][52][54] Optical coherence tomography studies of NMOSD-ON reveal profound peripapillary retinal nerve fiber layer thinning (averaging 38.4 micrometers, almost twofold higher than MS-ON) and macular ganglion cell and inner plexiform layer loss (1.5-fold greater than MS-ON), corresponding to the severe axonal loss characteristic of NMOSD.[32] Severe residual visual impairment persists in over one-third of NMOSD-ON patients despite treatment, with many left with acuity of 20/200 or worse, a rate substantially exceeding that in MS where over 90% of patients recover vision to 20/40 or better.[32]

Acute myelitis with longitudinally extensive transverse myelitis (LETM) lesions represents the other cardinal feature of NMOSD, defining the classic NMO presentation when simultaneous or sequential optic neuritis and myelitis occur.[1][4][21][52][54][55] Spinal cord involvement in NMOSD is frequently severe, causing complete spinal cord syndromes affecting motor, sensory, and autonomic pathways and resulting in paraplegia or tetraplegia.[1][21][52][55] The defining imaging characteristic of NMOSD myelitis is longitudinally extensive spinal cord involvement spanning three or more contiguous vertebral segments, involving predominantly central gray matter, and associated with cord swelling.[1][21][52][54][55] The central gray matter predominance reflects the anatomical distribution of AQP4, which is particularly concentrated in gray matter astrocytes surrounding the central canal.[1][21][52][55] Lesions typically involve the cervical or thoracic cord rather than the conus, show gadolinium enhancement on T1-weighted MRI, and characteristically display central hypointensity on T1 sequences and bright "spotty" hyperintensities on T2 sequences that are highly specific for NMOSD.[1][21][52][54][55] These MRI findings contrast sharply with MS-related myelitis, which typically involves shorter spinal cord segments (usually one vertebral segment or less), affects peripheral white matter tracts, and may be asymptomatic or cause only mild symptoms.[1][21][52]

Area postrema syndrome (APS) represents a distinctive NMOSD manifestation reflecting selective vulnerability of the area postrema to AQP4-IgG-mediated autoimmunity.[1][4][13][16][21][52][58] The area postrema, a circumventricular organ at the medullary floor of the fourth ventricle, expresses abundant AQP4 and lacks a functional blood-brain barrier, making it preferentially accessible to circulating AQP4-IgG.[13][16][52][58] APS presents with intractable hiccups, nausea, and vomiting that are often the initial NMOSD symptom and may precede optic neuritis or myelitis by days or weeks.[1][13][16][21][52][58] The symptoms reflect dysfunction of the area postrema's role in regulating emetic reflexes and autonomic functions; pathological studies demonstrate pronounced nonlytic reactive changes in astrocytes with abundant GFAP-positive cells showing activation and process extension, along with perivascular infiltration of lymphocytes and microglia.[13] Notably, area postrema involvement appears selective for NMOSD; while area postrema syndrome rarely occurs in MS, it is recognized in 10-44% of NMOSD patients depending on the cohort studied.[1][4][21][52]

Symptomatic narcolepsy and acute diencephalic syndromes with hypothalamic involvement represent emerging NMOSD manifestations reflecting AQP4 expression in hypothalamic astrocytes.[4][21][52][55][58] The hypothalamus contains hypocretin-1-producing neurons that regulate arousal and wakefulness, and AQP4-IgG-mediated damage to local astrocytes creates secondary dysfunction of these neurons, resulting in pathological sleepiness and cataplexy.[4][21][58] Diencephalic MRI lesions in NMOSD show characteristic periventricular involvement reflecting high AQP4 concentration at these sites.[4][21][52][55] Other brain and brainstem manifestations of NMOSD include acute brainstem syndromes with ataxia, nystagmus, vertigo, and trigeminal neuralgia reflecting lesions in the pons, medulla, and periaqueductal gray matter.[4][21][52][55] Brain lesions in NMOSD show preferential localization to periependymal regions abutting the ventricles, the medulla, dorsal pons, medial thalamus, and corpus callosum—regions with high AQP4 expression—contrasting with the periventricular and juxtacortical white matter distribution of MS lesions.[4][21][52][53][54][55] Notably, cortical lesions are virtually absent in AQP4-NMOSD despite being a hallmark of MS, reflecting the sparse expression of AQP4 in cortical regions.[4][53][54][55]

Disease Course, Relapse Patterns, and Disability Accumulation

NMOSD typically follows a relapsing course with recurrent acute inflammatory attacks separated by periods of relative stability, fundamentally distinct from the progressive forms of MS in which patients experience gradual worsening without discrete relapses.[1][4][21][31][34][46] The distinction between NMOSD and MS in patterns of disease progression has major implications for prognosis and treatment strategy. In NMOSD, neurological disability accumulates almost exclusively at the time of clinical attacks through stepwise acquisition of fixed deficits from each demyelinating episode, with minimal spontaneous improvement or deterioration occurring between relapses.[31][34] Approximately 67-90% of NMOSD patients experience relapses after the initial attack, with 49% experiencing relapses within the first year of disease onset.[1][32] The interval to first relapse varies widely from weeks to years, yet even patients in apparent long-term remission without attacks for years may subsequently relapse.[46] By contrast, MS frequently shows insidious progression independent of relapses, with continuous neurological decline occurring between discrete relapses, and permanent worsening accumulates through both relapse-related deficits and progressive degeneration.[31][34]

The severe cumulative disability that characterizes NMOSD reflects the catastrophic nature of individual attacks combined with incomplete recovery following treatment.[1][4][21][31][34] Even with modern immunosuppressive treatments, approximately 60% of NMOSD patients are functionally blind in at least one eye within 10 years of disease onset, and approximately 50% are mono- or paraplegic.[1][32] These disability rates are substantially higher than in MS, where severe visual loss occurs in only 4.2% of patients within 11 years of disease onset, and paraplegia is uncommon unless patients also have spinal cord involvement.[1][32] The irreversibility of NMOSD disability contrasts sharply with MS, where brain atrophy and progressive neurodegeneration occur but axonal loss and cellular death are less dramatic, and thus patients may experience some spontaneous recovery or stabilization of function.[31][34] Recent analyses have identified specific factors strongly associated with worse disability in NMOSD: increased age at disease onset, delayed diagnosis and initiation of preventive immunotherapy, longer acute myelitis lesions on MRI, and presence of brain or brainstem involvement.[33] Each decade increase in age at disease onset associates with 0.6 increase in EDSS score, delayed initiation of preventive treatment associates with 0.9 EDSS point increase per decade of delay, each additional spinal cord segment involved in acute myelitis associates with 0.16 EDSS point increase, and symptomatic brain/brainstem involvement associates with 0.91 point increase in EDSS.[33] These findings underscore the critical importance of early diagnosis and aggressive acute treatment of NMOSD attacks.

Current Therapeutic Approaches and Evidence for Mechanism-Based Treatment

Understanding of NMOSD pathophysiology has directly translated into development of multiple targeted therapeutic approaches, exemplifying how mechanistic knowledge of autoimmune diseases guides clinical therapy.[43][44] Acute attacks require immediate treatment to minimize irreversible axonal damage; first-line therapy consists of high-dose intravenous methylprednisolone (1 gram daily for 3-5 days) followed by oral prednisolone taper, which reduces inflammation and stabilizes the blood-brain barrier.[35][43] When steroid treatment fails to produce improvement or when attacks are severe, therapeutic plasma exchange (TPE) is administered, removing circulating pathogenic autoantibodies and complement factors from blood; TPE proves particularly effective when initiated within 7-11 days of attack onset, with studies showing better visual outcomes when combined with steroids than steroids alone.[35][43] Long-term relapse prevention represents the critical therapeutic focus for NMOSD, fundamentally distinct from MS where disease-modifying treatments address chronic progression independent of relapses.[43][44]

The traditional immunosuppressive agents mycophenolate mofetil and azathioprine reduce annualized relapse rates by approximately 70-90% in retrospective studies by suppressing proliferation of B cells and T cells through distinct mechanisms—inhibition of inosine monophosphate dehydrogenase in mycophenolate mofetil and purine synthesis inhibition in azathioprine.[43] More recent therapies target specific pathogenic mechanisms identified through mechanistic studies. Complement inhibitors including eculizumab (terminal C5 complement inhibitor) have proven highly effective, with clinical trials demonstrating 94% relative risk reduction in relapse rates, directly validating the centrality of complement-mediated astrocyte destruction in NMOSD pathogenesis.[43][44] The complement inhibitor mechanism prevents formation of the membrane attack complex (C5b-9) and also blocks generation of C5a, the potent neutrophil chemoattractant, thereby preventing both direct cytotoxic complement lysis of astrocytes and the secondary amplification of injury through PMN recruitment.[43][44]

IL-6 pathway inhibitors have emerged as highly effective therapies, including tocilizumab (anti-IL-6 receptor monoclonal antibody) and satralizumab (modified IL-6R antagonist), with clinical trial data showing approximately 78% reduction in relapse risk compared to standard immunosuppression.[43][44] The efficacy of IL-6 inhibition validates the critical role of IL-6 in multiple pathogenic mechanisms: IL-6 promotes differentiation of B cells into pathogenic plasmablasts that produce AQP4-IgG, IL-6 promotes Th17 cell differentiation that disrupts the blood-brain barrier, and IL-6 disrupts tight junction proteins directly through STAT3 signaling.[27][43][44] B cell-depleting therapies including rituximab (anti-CD20) and inebilizumab (anti-CD19) reduce relapse rates by 77-97%, directly targeting the cells responsible for producing pathogenic AQP4-IgG.[43][44][49] The efficacy of these diverse mechanistically-targeted therapies demonstrates that NMOSD pathogenesis involves redundant pathways through which disease can be interrupted at multiple points—whether by blocking complement-mediated cytotoxicity, suppressing IL-6-driven B cell activation, or directly eliminating pathogenic B cells.[43][44]

Conclusion: Integrated Understanding of NMOSD Pathophysiology

Neuromyelitis optica spectrum disorder represents a paradigmatic example of how discovery of a specific autoimmune target—in this case the aquaporin-4 water channel protein—can illuminate the entire disease mechanism and guide rational therapeutic development.[1][3][4][7] The disease results not from a single pathophysiological process but rather from an interconnected cascade of molecular, cellular, and anatomical factors that converge to produce irreversible CNS damage. The primary pathogenic mechanism involves circulating IgG autoantibodies against AQP4 entering the CNS through naturally permeable regions including the area postrema, binding to their target antigen on astrocyte membranes, activating the complement cascade through multivalent clustering of AQP4 molecules, and directing formation of the membrane attack complex that disrupts astrocyte cell membranes and leads to their death.[3][7][29] This primary astrocyte destruction triggers a cascade of secondary pathological events: loss of astrocytic homeostatic functions creates osmotic stress and ionic imbalance in adjacent axons; complement activation recruits polymorphonuclear leukocytes that degrade blood-brain barrier tight junctions and amplify inflammation; microglia and macrophages become activated and produce additional proinflammatory cytokines including IL-6 and TNF-α; T cell responses shift toward pathogenic Th17 phenotypes through IL-6-dependent mechanisms; and soluble complement fragments deposit on nearby oligodendrocytes and neurons through bystander mechanisms, causing their secondary death through both complementary and cellular pathways.[3][7][14][29][37][39][42]

The consequence of this pathophysiological cascade is irreversible neurological disability that accumulates in stepwise fashion with each relapsing attack, reflecting the profound axonal loss and neuronal death that characterize NMOSD neuropathology.[3][7][21][31][34][45] The selective anatomical targeting of AQP4-rich CNS regions including the optic nerves, spinal cord, and brain regions with high astrocytic AQP4 expression creates the distinctive clinical phenotype of NMOSD—with profound visual impairment, paraplegia, and autonomic dysfunction predominating.[1][4][21][52] The understanding of NMOSD pathophysiology has motivated development of multiple targeted therapies addressing different points in the pathogenic cascade—complement inhibitors preventing membrane attack complex formation, IL-6 inhibitors suppressing both B cell activation and Th17 differentiation, and B cell-depleting therapies eliminating the cells responsible for pathogenic autoantibody production.[43][44] The continued investigation into disease mechanisms, particularly regarding how AQP4-IgG initially breaches the blood-brain barrier, how double-negative NMOSD develops in the absence of known autoantibodies, and how astrocyte regeneration occurs following acute destruction, promises to further refine therapeutic approaches and potentially identify neuroprotective strategies that could improve outcomes for this devastating disease.